Angela Dispenzieri

List of Publications by Year
in descending order

1,175	75,441	527 127	1082 232
papers	citations	h-index	g-index

1197	1197	1197	28062
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	5.1	3,343
2	Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008, 111, 2516-2520.	0.6	2,022
3	Review of 1027 Patients With Newly Diagnosed Multiple Myeloma. Mayo Clinic Proceedings, 2003, 78, 21-33.	1.4	1,904
4	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
5	Prevalence of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2006, 354, 1362-1369.	13.9	1,135
6	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia, 2014, 28, 1122-1128.	3.3	1,128
7	Promiscuous Mutations Activate the Noncanonical NF-ÎºB Pathway in Multiple Myeloma. Cancer Cell, 2007, 12, 131-144.	7.7	941
8	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood, 2009, 113, 5412-5417.	0.6	904
9	Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. Journal of Clinical Oncology, 2012, 30, 989-995.	0.8	837
10	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. Journal of Clinical Oncology, 2004, 22, 3751-3757.	0.8	774
11	Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. New England Journal of Medicine, 2007, 356, 2582-2590.	13.9	740
12	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. Journal of Clinical Oncology, 2012, 30, 4541-4549.	0.8	735
13	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. New England Journal of Medicine, 2014, 371, 906-917.	13.9	697
14	POEMS syndrome: definitions and long-term outcome. Blood, 2003, 101, 2496-2506.	0.6	694
15	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia, 2009, 23, 215-224.	3.3	686
16	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet, The, 2017, 389, 519-527.	6.3	684
17	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	3.3	664
18	Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 2005, 106, 4050-4053.	0.6	604

#	Article	IF	Citations
19	Clonal competition with alternating dominance in multiple myeloma. Blood, 2012, 120, 1067-1076.	0.6	575
20	Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood, 2005, 106, 812-817.	0.6	557
21	IMWG consensus on risk stratification in multiple myeloma. Leukemia, 2014, 28, 269-277.	3.3	500
22	Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma. Journal of Clinical Oncology, 2002, 20, 4319-4323.	0.8	479
23	Natural History of Wild-Type TransthyretinÂCardiac Amyloidosis andÂRisk Stratification Using a NovelÂStaging System. Journal of the American College of Cardiology, 2016, 68, 1014-1020.	1.2	460
24	Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood, 2012, 120, 4292-4295.	0.6	447
25	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.	1.4	440
26	Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2010, 3, 155-164.	2.3	431
27	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2018, 378, 241-249.	13.9	392
28	Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clinic Proceedings, 2009, 84, 1095-1110.	1.4	389
29	International, evidence-based consensus diagnostic criteria for HHV-8â€“negative/idiopathic multicentric Castleman disease. Blood, 2017, 129, 1646-1657.	0.6	381
30	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood, 2008, 111, 785-789.	0.6	355
31	Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers, 2018, 4, 38.	18.1	350
32	Diagnosis of monoclonal gammopathy of renal significance. Kidney International, 2015, 87, 698-711.	2.6	339
33	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	1.2	338
34	Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood, 2005, 106, 2837-2840.	0.6	337
35	Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia, 2012, 26, 2317-2325.	3.3	332
36	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	4.1	330

#	Article	IF	Citations
37	POEMS syndrome. Blood Reviews, 2007, 21, 285-299.	2.8	327
38	Clinical Course of Patients With Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2004, 79, 867-874.	1.4	319
39	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation, 2019, 139, 431-443.	1.6	319
40	Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia, 2007, 21, 2035-2042.	3.3	317
41	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet, The, 2010, 375, 1721-1728.	6.3	313
42	Left Ventricular Amyloid Deposition inÂPatientsÂWith Heart Failure andÂPreservedÂEjection Fraction. JACC: Heart Failure, 2014, 2, 113-122.	1.9	309
43	Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging. JAMA Cardiology, 2016, 1, 880.	3.0	304
44	Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 2004, 104, 1881-1887.	0.6	300
45	Genetic aberrations and survival in plasma cell leukemia. Leukemia, 2008, 22, 1044-1052.	3.3	299
46	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 5008-5014.	0.8	286
47	Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet, The, 2003, 361, 1787-1789.	6.3	277
48	Screening Panels for Detection of Monoclonal Gammopathies. Clinical Chemistry, 2009, 55, 1517-1522.	1.5	268
49	The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 2007, 109, 465-470.	0.6	259
50	How I treat monoclonal gammopathy of renal significance (MGRS). Blood, 2013, 122, 3583-3590.	0.6	259
51	The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood, 2003, 102, 2562-2567.	0.6	257
52	Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood, 2001, 98, 579-585.	0.6	253
53	Prognostic value of bone marrow angiogenesis in multiple myeloma. Clinical Cancer Research, 2000, 6, 3111-6.	3.2	252
54	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood, 2017, 129, 2111-2119.	0.6	249

#	Article	IF	Citations
55	Diagnostic Performance of Quantitative Îº and Î» Free Light Chain Assays in Clinical Practice. Clinical Chemistry, 2005, 51, 878-881.	1.5	244
56	Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. Mayo Clinic Proceedings, 2014, 89, 926-933.	1.4	240
57	Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. Cancer Research, 2007, 67, 2982-2989.	0.4	236
58	Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1Î²-Induced Interleukin 6 Production and the Myeloma Proliferative Component. Mayo Clinic Proceedings, 2009, 84, 114-122.	1.4	236
59	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 2018, 132, 2115-2124.	0.6	232
60	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 2006, 107, 3378-3383.	0.6	230
61	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	1.4	230
62	Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood, 2004, 103, 3960-3963.	0.6	226
63	The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nature Reviews Nephrology, 2012, 8, 43-51.	4.1	226
64	Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma. Mayo Clinic Proceedings, 2006, 81, 1047-1053.	1.4	221
65	Thalidomide as initial therapy for early-stage myeloma. Leukemia, 2003, 17, 775-779.	3.3	219
66	Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clinical Cancer Research, 2002, 8, 2210-6.	3.2	219
67	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood, 2012, 119, 2100-2105.	0.6	218
68	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood, 2018, 131, 301-310.	0.6	216
69	Overview of Castleman disease. Blood, 2020, 135, 1353-1364.	0.6	216
70	Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood, 2005, 106, 2276-2279.	0.6	213
71	Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia, 2003, 17, 427-436.	3.3	208
72	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia, 2009, 23, 1904-1912.	3.3	207

#	Article	IF	Citations
73	Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood, 2004, 104, 3400-3407.	0.6	204
74	Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia, 2013, 27, 941-946.	3.3	201
75	Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia, 2006, 20, 2034-2040.	3.3	195
76	Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia, 2013, 27, 1738-1744.	3.3	194
77	Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood, 2011, 118, 2970-2975.	0.6	193
78	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology, 2013, 31, 4319-4324.	0.8	193
79	A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia, 2007, 21, 529-534.	3.3	191
80	POEMS Syndrome: 2019 Update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2019, 94, 812-827.	2.0	190
81	Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney. Journal of the American Society of Nephrology: JASN, 2011, 22, 1129-1136.	3.0	188
82	The clinical spectrum of Castleman's disease. American Journal of Hematology, 2012, 87, 997-1002.	2.0	184
83	Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia, 2010, 24, 1934-1939.	3.3	182
84	Monoclonal Gammopathy of Undetermined Significance, WaldenstrÃ¶m Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment. Mayo Clinic Proceedings, 2006, 81, 693-703.	1.4	181
85	Elimination of the Need for Urine Studies in the Screening Algorithm for Monoclonal Gammopathies by Using Serum Immunofixation and Free Light Chain Assays. Mayo Clinic Proceedings, 2006, 81, 1575-1578.	1.4	179
86	The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood, 2011, 118, 4663-4665.	0.6	176
87	Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney Biopsies. American Journal of Kidney Diseases, 2012, 59, 786-794.	2.1	174
88	Thalidomide in the Treatment of Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2000, 75, 897-901.	1.4	173
89	POEMS syndrome: 2011 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2011, 86, 591-601.	2.0	173
90	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood, 2018, 132, 1478-1485.	0.6	173

#	Article	IF	Citations
91	High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases. Journal of Clinical Oncology, 2002, 20, 189-196.	0.8	172
92	Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney International, 2008, 73, 1282-1288.	2.6	171
93	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	2.8	171
94	Gene-expression profiling of Waldenstrol̂m macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood, 2006, 108, 2755-2763.	0.6	166
95	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. Mayo Clinic Proceedings, 2011, 86, 12-18.	1.4	164
96	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology, 2015, 33, 3741-3749.	0.8	163
97	Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients. Mayo Clinic Proceedings, 2009, 84, 685-693.	1.4	159
98	Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia, 2011, 25, 906-908.	3.3	159
99	Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplantation, 2013, 48, 557-561.	1.3	158
100	Stem cell transplantation for the management of primary systemic amyloidosis. American Journal of Medicine, 2002, 113, 549-555.	0.6	157
101	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clinic Proceedings, 2007, 82, 323-341.	1.4	155
102	Eligibility for Hematopoietic Stem-Cell Transplantation for Primary Systemic Amyloidosis Is a Favorable Prognostic Factor for Survival. Journal of Clinical Oncology, 2001, 19, 3350-3356.	0.8	154
103	Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood, 2006, 108, 1979-1983.	0.6	152
104	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. Mayo Clinic Proceedings, 2010, 85, 824-833.	1.4	152
105	Systemic Amyloidosis Recognition, Prognosis, and Therapy. JAMA - Journal of the American Medical Association, 2020, 324, 79.	3.8	152
106	Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia, 2001, 15, 1274-1276.	3.3	151
107	Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis. Journal of Cardiovascular Electrophysiology, 2013, 24, 793-798.	0.8	148
108	Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart, 2017, 103, 1065-1072.	1.2	148

#	Article	IF	Citations
109	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 4529-4535.	0.8	147
110	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood, 2010, 116, 5126-5129.	0.6	146
111	Vascular endothelial growth factor and POEMS. Neurology, 2006, 66, 10-12.	1.5	145
112	Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia, 2008, 22, 1933-1937.	3.3	144
113	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood, 2012, 119, 5397-5404.	0.6	144
114	P<scp>OEMS</scp> syndrome: 2017 Update on diagnosis, risk stratification, and management. American Journal of Hematology, 2017, 92, 814-829.	2.0	144
115	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clinic Proceedings, 2007, 82, 323-341.	1.4	143
116	Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana. Mayo Clinic Proceedings, 2007, 82, 1468-1473.	1.4	142
117	Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Mayo Clinic Proceedings, 2007, 82, 1179-1184.	1.4	142
118	Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12â€‰482 persons from the National Health and Nutritional Examination Survey. Leukemia, 2014, 28, 1537-1542.	3.3	142
119	AMYLOIDOSIS. Hematology/Oncology Clinics of North America, 1999, 13, 1211-1233.	0.9	141
120	Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica, 2014, 99, 1239-1247.	1.7	140
121	High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia, 2013, 27, 680-685.	3.3	138
122	Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood, 2010, 116, 1056-1059.	0.6	137
123	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia, 2009, 23, 1716-1730.	3.3	136
124	Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood, 2001, 98, 2266-2268.	0.6	135
125	Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood, 2012, 120, 56-62.	0.6	133
126	IAP antagonists induce anti-tumor immunity in multiple myeloma. Nature Medicine, 2016, 22, 1411-1420.	15.2	133

#	Article	IF	Citations
127	Systemic amyloidosis from A (AA) to T (ATTR): a review. Journal of Internal Medicine, 2021, 289, 268-292.	2.7	133
128	Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2010, 28, 1408-1414.	0.8	132
129	Neurological aspects of multiple myeloma and related disorders. Best Practice and Research in Clinical Haematology, 2005, 18, 673-688.	0.7	131
130	Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer Journal, 2020, 10, 53.	2.8	131
131	Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis. Journal of the American College of Cardiology, 2020, 75, 2851-2862.	1.2	131
132	Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood, 2009, 114, 518-521.	0.6	130
133	Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia, 2006, 20, 807-813.	3.3	129
134	Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood, 2004, 104, 40-42.	0.6	128
135	Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. British Journal of Haematology, 2006, 133, 158-164.	1.2	128
136	Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney International, 2010, 77, 721-728.	2.6	128
137	Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood, 2009, 114, 785-790.	0.6	127
138	Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 257-261.	1.4	126
139	Vertebroplasty in Multiple Myeloma: Outcomes in a Large Patient Series. American Journal of Neuroradiology, 2008, 29, 642-648.	1.2	126
140	POEMS syndrome: 2021 Update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2021, 96, 872-888.	2.0	126
141	Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. American Journal of Hematology, 2008, 83, 614-617.	2.0	123
142	POEMS syndrome: 2014 Update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2014, 89, 213-223.	2.0	123
143	Pathophysiology and treatment of cardiac amyloidosis. Nature Reviews Cardiology, 2015, 12, 91-102.	6.1	123
144	Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2003, 78, 34-39.	1.4	122

#	Article	IF	Citations
145	Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. Clinical Chemistry, 2016, 62, 1334-1344.	1.5	122
146	Appraisal of immunoglobulin free light chain as a marker of response. Blood, 2008, 111, 4908-4915.	0.6	121
147	Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia, 2017, 31, 2791-2798.	3.3	120
148	Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood, 2010, 115, 1343-1350.	0.6	119
149	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 2012, 119, 4860-4867.	0.6	119
150	Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 480-486.	0.9	118
151	Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide. Clinical Pharmacology and Therapeutics, 2007, 82, 700-710.	2.3	117
152	Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid Cardiomyopathy. Journal of Heart and Lung Transplantation, 2008, 27, 823-829.	0.3	117
153	Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. European Journal of Haematology, 2008, 80, 397-406.	1.1	116
154	Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal Gammopathy. Journal of Proteome Research, 2014, 13, 1419-1427.	1.8	116
155	Direct Current Cardioversion of AtrialÂArrhythmias in Adults With CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2019, 73, 589-597.	1.2	116
156	Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clinic Proceedings, 2001, 76, 476-487.	1.4	115
157	A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood, 2005, 106, 2156-2161.	0.6	115
158	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	1.4	115
159	Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica, 2007, 92, 1415-1418.	1.7	114
160	Progression in smoldering WaldenstrÃ¶m macroglobulinemia: long-term results. Blood, 2012, 119, 4462-4466.	0.6	113
161	Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis. American Journal of Cardiology, 2014, 113, 1723-1727.	0.7	112
162	Discordance between serum cardiac biomarker and immunoglobulinâ€free lightâ€chain response in patients with immunoglobulin lightâ€chain amyloidosis treated with immune modulatory drugs. American Journal of Hematology, 2010, 85, 757-759.	2.0	111

#	Article	IF	Citations
163	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood, 2014, 124, 907-912.	0.6	111
164	Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance. Journal of Clinical Oncology, 2005, 23, 5668-5674.	0.8	110
165	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	3.4	110
166	6q deletion in WaldenstrÃ¶m macroglobulinemia is associated with features of adverse prognosis. British Journal of Haematology, 2007, 136, 80-86.	1.2	109
167	Mass Spectrometryâ€“Based Proteomic Diagnosis of Renal Immunoglobulin Heavy Chain Amyloidosis. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2180-2187.	2.2	109
168	Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia, 2014, 28, 2060-2065.	3.3	109
169	Amyloidosis: Recognition, Confirmation, Prognosis, and Therapy. Mayo Clinic Proceedings, 1999, 74, 490-494.	1.4	108
170	Evidence of Impaired Left Ventricular Systolic Function by Doppler Myocardial Imaging in Patients With Systemic Amyloidosis and No Evidence of Cardiac Involvement by Standard Two-Dimensional and Doppler Echocardiography. American Journal of Cardiology, 2008, 101, 1039-1045.	0.7	108
171	Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplantation, 2009, 43, 619-625.	1.3	108
172	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood, 2017, 130, 597-605.	0.6	108
173	MYC dysregulation in the progression of multiple myeloma. Leukemia, 2020, 34, 322-326.	3.3	108
174	Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Experimental Hematology, 2006, 34, 713-720.	0.2	107
175	Detection of Left Ventricular Systolic Dysfunction in Cardiac Amyloidosis with Strain Rate Echocardiography. Journal of the American Society of Echocardiography, 2007, 20, 1194-1202.	1.2	107
176	Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Current Cancer Drug Targets, 2018, 18, 177-187.	0.8	107
177	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	0.7	107
178	Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clinic Proceedings, 2009, 84, 685-93.	1.4	107
179	Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrology Dialysis Transplantation, 2009, 24, 3132-3137.	0.4	106
180	How I treat POEMS syndrome. Blood, 2012, 119, 5650-5658.	0.6	106

#	Article	IF	Citations
181	What do I need to know about immunoglobulin light chain (AL) amyloidosis?. Blood Reviews, 2012, 26, 137-154.	2.8	106
182	Early versus delayed autologous transplantation after immunomodulatory agentsâ€based induction therapy in patients with newly diagnosed multiple myeloma. Cancer, 2012, 118, 1585-1592.	2.0	106
183	Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2015, 90, 1054-1081.	1.4	106
184	Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana. Mayo Clinic Proceedings, 2007, 82, 1468-1473.	1.4	106
185	Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood, 2003, 101, 1715-1717.	0.6	105
186	6q deletion discriminates WaldenstrÃ¶m macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genetics and Cytogenetics, 2006, 169, 150-153.	1.0	105
187	Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clinic Proceedings, 2020, 95, 1852-1864.	1.4	105
188	Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia, 2011, 25, 689-696.	3.3	104
189	Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplantation, 2004, 34, 1025-1031.	1.3	102
190	Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leukemia and Lymphoma, 2010, 51, 2181-2187.	0.6	102
191	POEMS syndrome: Update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2012, 87, 804-814.	2.0	102
192	The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney International, 2013, 83, 463-470.	2.6	101
193	Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood, 2003, 101, 2156-2158.	0.6	100
194	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. Journal of Clinical Oncology, 2018, 36, 1323-1329.	0.8	100
195	The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia, 2004, 18, 1085-1092.	3.3	99
196	Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 1615-1624.	2.0	99
197	Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood, 2017, 129, 299-306.	0.6	99
198	Independent Predictors of Survival in Primary Systemic (AL) Amyloidosis, Including Cardiac Biomarkers and Left Ventricular Strain Imaging: An Observational Cohort Study. Journal of the American Society of Echocardiography, 2010, 23, 643-652.	1.2	98

#	Article	IF	Citations
199	Use of Nonclonal Serum Immunoglobulin Free Light Chains to Predict Overall Survival in the General Population. Mayo Clinic Proceedings, 2012, 87, 517-523.	1.4	98
200	Salvage Second Hematopoietic Cell Transplantation inÂMyeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 760-766.	2.0	98
201	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2014, 20, 402-408.e1.	2.0	98
202	Endocrinopathy in POEMS Syndrome: The Mayo Clinic Experience. Mayo Clinic Proceedings, 2007, 82, 836-842.	1.4	97
203	Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood, 2011, 117, 6438-6444.	0.6	97
204	Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer Journal, 2013, 3, e143-e143.	2.8	97
205	<scp>POEMS</scp> syndrome: Update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2015, 90, 951-962.	2.0	97
206	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	1.4	97
207	Lenalidomide therapy in a patient with POEMS syndrome. Blood, 2007, 110, 1075-1076.	0.6	95
208	Immunoglobulin light chain amyloidosis and the kidney. Kidney International, 2002, 61, 1-9.	2.6	94
209	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica, 2009, 94, 380-386.	1.7	94
210	Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition. Mayo Clinic Proceedings, 2012, 87, 1071-1079.	1.4	94
211	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Advances, 2020, 4, 6039-6050.	2.5	94
212	Pulmonary Manifestations in Patients With POEMS Syndrome. Chest, 2008, 133, 969-974.	0.4	93
213	The utility of MASSâ€FIX to detect and monitor monoclonal proteins in the clinic. American Journal of Hematology, 2017, 92, 772-779.	2.0	93
214	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	4.9	93
215	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. Mayo Clinic Proceedings, 2015, 90, 587-596.	1.4	92
216	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia, 2017, 31, 1562-1569.	3.3	92

#	Article	IF	Citations
217	Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. European Heart Journal Cardiovascular Imaging, 2012, 13, 680-689.	0.5	91
218	Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia, 2013, 27, 208-212.	3.3	91
219	Natural history and therapy of AL cardiac amyloidosis. Heart Failure Reviews, 2015, 20, 155-162.	1.7	91
220	Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. European Heart Journal, 2005, 26, 173-179.	1.0	90
221	Clinical implication of centrosome amplification in plasma cell neoplasm. Blood, 2006, 107, 3669-3675.	0.6	90
222	Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. Mayo Clinic Proceedings, 2008, 83, 1131-1135.	1.4	90
223	Cerebral infarction in POEMS syndrome. Neurology, 2009, 73, 1308-1312.	1.5	90
224	IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. American Journal of Hematology, 2010, 85, 853-855.	2.0	90
225	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2015, 5, e296-e296.	2.8	90
226	DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 51-56.	3.0	90
227	Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia, 2004, 18, 624-627.	3.3	88
228	Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrology Dialysis Transplantation, 2011, 26, 2032-2036.	0.4	88
229	Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplantation, 2008, 42, 413-420.	1.3	87
230	Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrology Dialysis Transplantation, 2008, 23, 2052-2057.	0.4	87
231	Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia, 2016, 30, 2208-2213.	3.3	87
232	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clinic Proceedings, 2019, 94, 465-471.	1.4	87
233	Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia, 2012, 26, 1091-1097.	3.3	85
234	A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia, 2013, 27, 220-225.	3.3	85

#	Article	IF	Citations
235	Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Therapy, 2013, 20, 255-261.	2.3	85
236	Living Donor Kidney and Autologous Stem Cell Transplantation for Primary Systemic Amyloidosis (AL) with Predominant Renal Involvement. American Journal of Transplantation, 2005, 5, 1660-1670.	2.6	83
237	Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leukemia and Lymphoma, 2008, 49, 36-41.	0.6	83
238	Idiotypeâ€pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. American Journal of Hematology, 2009, 84, 799-802.	2.0	83
239	Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 123-131.	1.4	83
240	Prognosis of Light Chain Amyloidosis WithÂPreserved LVEF. JACC: Cardiovascular Imaging, 2017, 10, 398-407.	2.3	83
241	CRYOGLOBULINEMIA. Hematology/Oncology Clinics of North America, 1999, 13, 1315-1349.	0.9	82
242	High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplantation, 2004, 34, 161-167.	1.3	82
243	Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10â€“49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer Journal, 2017, 7, e618-e618.	2.8	82
244	Quantification of clonal circulating plasma cells in relapsed multiple myeloma. British Journal of Haematology, 2014, 167, 500-505.	1.2	81
245	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer Journal, 2015, 5, e364-e364.	2.8	81
246	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	1.3	81
247	Ocular Findings in Patients with Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. Ophthalmology, 2011, 118, 778-782.	2.5	80
248	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 384-388.	1.4	79
249	Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Current Opinion in Molecular Therapeutics, 2009, 11, 43-53.	2.8	79
250	Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood, 2007, 109, 1228-1232.	0.6	78
251	Changes in serumâ€free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. American Journal of Hematology, 2011, 86, 251-255.	2.0	78
252	High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood, 2012, 119, 1117-1122.	0.6	78

#	Article	IF	Citations
253	Transplantation for amyloidosis. Current Opinion in Oncology, 2007, 19, 136-141.	1.1	77
254	Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood, 2011, 118, 1979-1988.	0.6	77
255	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer Journal, 2021, 11, 24.	2.8	77
256	Dermatologic Adverse Effects of Lenalidomide Therapy for Amyloidosis and Multiple Myeloma. Archives of Dermatology, 2006, 142, 1298-302.	1.7	76
257	Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization. Biology of Blood and Marrow Transplantation, 2013, 19, 87-93.	2.0	76
258	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. American Journal of Hematology, 2015, 90, 181-186.	2.0	76
259	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	2.0	76
260	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. American Journal of Hematology, 2017, 92, 668-673.	2.0	75
261	Renal Response After High-Dose Melphalan and Stem Cell Transplantation Is a Favorable Marker in Patients With Primary Systemic Amyloidosis. American Journal of Kidney Diseases, 2005, 46, 270-277.	2.1	74
262	POEMS Syndrome. Hematology American Society of Hematology Education Program, 2005, 2005, 360-367.	0.9	74
263	Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.. Bone Marrow Transplantation, 2013, 48, 1302-1307.	1.3	74
264	Outcomes of patients with POEMS syndrome treated initially with radiation. Blood, 2013, 122, 68-73.	0.6	74
265	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1796-1803.	2.0	73
266	Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia, 2016, 30, 1979-1986.	3.3	73
267	Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplantation, 2000, 25, 465-470.	1.3	72
268	Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathyâ€"Related Kidney Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1964-1968.	2.2	72
269	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	1.4	72
270	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia, 2019, 33, 531-536.	3.3	72

#	Article	IF	Citations
271	Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis. PLoS ONE, 2009, 4, e5169.	1.1	72
272	Nâ€terminal fragment of the typeâ€B natriuretic peptide (NTâ€proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	2.0	71
273	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with WaldenstrÃ¶m macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	0.8	71
274	Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. British Journal of Haematology, 2008, 141, 792-798.	1.2	70
275	Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood, 2009, 114, 4928-4932.	0.6	70
276	Smoldering multiple myeloma requiring treatment: time for a new definition?. Blood, 2013, 122, 4172-4181.	0.6	70
277	Leukocyte cell-derived chemotaxin 2 (LECT2)â€“associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood, 2014, 123, 1479-1482.	0.6	70
278	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€”Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	0.7	70
279	Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood, 2003, 101, 827-830.	0.6	69
280	Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma. Mayo Clinic Proceedings, 2010, 85, 232-238.	1.4	69
281	Trends and outcomes of modern staging of solitary plasmacytoma of bone. American Journal of Hematology, 2012, 87, 647-651.	2.0	69
282	Amyloidosis. Best Practice and Research in Clinical Haematology, 2005, 18, 709-727.	0.7	68
283	Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma. Clinical Cancer Research, 2007, 13, 6162-6167.	3.2	68
284	Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer Journal, 2015, 5, e338-e338.	2.8	68
285	LGE Provides Incremental Prognostic Information OverÂSerum Biomarkers in ALÂCardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2016, 9, 680-686.	2.3	68
286	High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Blood Cancer Journal, 2017, 7, e590-e590.	2.8	68
287	Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. Bone Marrow Transplantation, 2001, 28, 305-309.	1.3	67
288	Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification: Implications for Monitoring Monoclonal Gammopathies. Clinical Chemistry, 2011, 57, 1687-1692.	1.5	67

#	Article	IF	Citations
289	Natural history of t(11;14) multiple myeloma. Leukemia, 2018, 32, 131-138.	3.3	67
290	Expert review on softâ€tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	1.2	67
291	Treatment of castlemanâ€™s disease. Current Treatment Options in Oncology, 2005, 6, 255-266.	1.3	66
292	Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplantation, 2006, 37, 1003-1008.	1.3	66
293	Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer Journal, 2018, 8, 67.	2.8	66
294	Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2021, 6, 1267.	3.0	66
295	Left ventricular device implantation for advanced cardiac amyloidosis. Journal of Heart and Lung Transplantation, 2013, 32, 563-568.	0.3	65
296	Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood, 2006, 107, 3384-3388.	0.6	64
297	Biologic and genetic characterization of the novel amyloidogenic lambda light chainâ€“secreting human cell lines, ALMC-1 and ALMC-2. Blood, 2008, 112, 1931-1941.	0.6	64
298	Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. Kidney International, 2009, 75, 420-427.	2.6	64
299	Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 335-341.	2.0	64
300	Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis. Journal of Cardiovascular Electrophysiology, 2016, 27, 1167-1173.	0.8	64
301	Ocular Manifestations of Familial Transthyretin Amyloidosis. American Journal of Ophthalmology, 2017, 183, 156-162.	1.7	64
302	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	3.3	64
303	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	2.8	64
304	Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Leukemia, 2020, 34, 3310-3322.	3.3	64
305	Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplantation, 2011, 46, 970-975.	1.3	63
306	High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart, 2014, 100, 383-388.	1.2	63

#	Article	IF	Citations
307	Cardiac MR elastography for quantitative assessment of elevated myocardial stiffness in cardiac amyloidosis. Journal of Magnetic Resonance Imaging, 2017, 46, 1361-1367.	1.9	63
308	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia, 2017, 31, 130-135.	3.3	63
309	Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplantation, 2004, 34, 235-239.	1.3	62
310	Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer Journal, 2015, 5, e310-e310.	2.8	62
311	Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. American Journal of Hematology, 2001, 68, 269-275.	2.0	61
312	Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrology Dialysis Transplantation, 2012, 27, 1097-1101.	0.4	61
313	Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome. Neurology, 2015, 84, 1981-1987.	1.5	61
314	Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell Transplantation. Archives of Dermatology, 2005, 141, 1277-82.	1.7	60
315	Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia, 2014, 28, 398-403.	3.3	60
316	Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia, 2018, 32, 986-995.	3.3	60
317	Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Reviews, 2004, 18, 17-37.	2.8	59
318	Multiple myeloma: clinical features and indications for therapy. Best Practice and Research in Clinical Haematology, 2005, 18, 553-568.	0.7	59
319	Natural history and therapy of 66 patients with mixed cryoglobulinemia. American Journal of Hematology, 2006, 81, 511-518.	2.0	59
320	Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood, 2010, 116, 2019-2025.	0.6	59
321	Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood, 2011, 118, 1763-1765.	0.6	59
322	Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplantation, 2013, 48, 568-573.	1.3	59
323	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometryâ€"Verified Typing. Mayo Clinic Proceedings, 2019, 94, 472-483.	1.4	59
324	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal, 2020, 10, 82.	2.8	59

#	Article	IF	Citations
325	Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics. Current Pharmaceutical Biotechnology, 2012, 13, 1732-1741.	0.9	58
326	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances, 2020, 4, 3509-3519.	2.5	58
327	Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation, 2007, 39, 605-611.	1.3	57
328	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology, 2011, 86, 640-645.	2.0	57
329	Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplantation, 2011, 46, 943-949.	1.3	57
330	Tenâ€year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer, 2012, 118, 6105-6109.	2.0	57
331	Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays. Clinical Chemistry, 2015, 61, 360-367.	1.5	57
332	Longâ€term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology, 2016, 91, 585-589.	2.0	57
333	Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. Acta Haematologica, 2016, 135, 172-190.	0.7	57
334	Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration. Clinical Chemistry, 2016, 62, 243-251.	1.5	57
335	Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia, 2016, 30, 633-639.	3.3	57
336	Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. Journal of the American Society of Nephrology: JASN, 2017, 28, 439-445.	3.0	57
337	Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer Journal, 2017, 7, e600-e600.	2.8	57
338	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 86-92.	1.4	57
339	MYD88 mutation status does not impact overall survival in WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	2.0	57
340	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer Journal, 2019, 9, 102.	2.8	57
341	PS-341â€“mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Experimental Hematology, 2005, 33, 784-795.	0.2	56
342	Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia, 2011, 25, 1344-1353.	3.3	56

#	Article	IF	Citations
343	Monitoring M-Proteins in Patients with Multiple Myeloma Using Heavy-Chain Variable Region Clonotypic Peptides and LCâ€“MS/MS. Journal of Proteome Research, 2014, 13, 1905-1910.	1.8	56
344	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer Journal, 2016, 6, e454-e454.	2.8	56
345	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World Journal of Transplantation, 2016, 6, 380.	0.6	56
346	Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplantation, 2000, 26, 979-983.	1.3	55
347	Deletions of 17p13.1 and 13q14 are uncommon in WaldenstrÃ¶m macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genetics and Cytogenetics, 2002, 132, 55-60.	1.0	55
348	Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Mayo Clinic Proceedings, 2010, 85, 532-537.	1.4	55
349	A multicenter phase II trial of 4â€²-iodo-4â€²-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 24-30.	1.4	54
350	Amyloidosis: Diagnosis and Management. Clinical Lymphoma and Myeloma, 2005, 6, 208-219.	1.4	54
351	Tumorâ€associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. American Journal of Hematology, 2009, 84, 401-407.	2.0	54
352	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood, 2017, 130, 1198-1204.	0.6	54
353	The Neuropathies of WaldenstrÃ¶m's Macroglobulinemia (WM) and IgM-MGUS. Canadian Journal of Neurological Sciences, 2011, 38, 289-295.	0.3	53
354	Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. The Cochrane Library, 2012, , CD006828.	1.5	53
355	Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood, 2013, 121, 3147-3152.	0.6	53
356	A predictive model for risk of early gradeâ€‰â€¥â€‰3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia, 2018, 32, 1404-1413.	3.3	53
357	Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients. Leukemia, 2019, 33, 254-257.	3.3	53
358	Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplantation, 2003, 32, 317-324.	1.3	52
359	Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplantation, 2004, 34, 485-490.	1.3	52
360	Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood, 2005, 105, 794-803.	0.6	52

#	Article	IF	Citations
361	Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplantation, 2006, 37, 1017-1022.	1.3	52
362	Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovascular Pathology, 2013, 22, 189-194.	0.7	52
363	Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. Haematologica, 2018, 103, e135-e137.	1.7	52
364	Vascular abnormalities in primary amyloidosis. European Heart Journal, 2007, 28, 1019-1024.	1.0	51
365	Second transplants for multiple myeloma relapsing after a previous autotransplantâ€"reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplantation, 2014, 49, 416-421.	1.3	51
366	Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplantation, 2016, 51, 1449-1455.	1.3	51
367	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood, 2016, 128, 2415-2422.	0.6	51
368	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	1.3	51
369	Two-dimensional acoustic pattern derived strain parameters closely correlate with one-dimensional tissue Doppler derived strain measurements. European Journal of Echocardiography, 2006, 7, 315-321.	2.3	50
370	IgM Monoclonal Gammopathy of Undetermined Significance and Smoldering WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 17-18.	1.4	50
371	Clinical course and prognosis of nonâ€ssecretory multiple myeloma. European Journal of Haematology, 2015, 95, 57-64.	1.1	50
372	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood, 2017, 129, 82-87.	0.6	50
373	Amyloidosis: Recognition, Confirmation, Prognosis, and Therapy. Mayo Clinic Proceedings, 1999, 74, 490-494.	1.4	49
374	Clarithromycin (Biaxin)â€lenalidomideâ€lowâ€dose dexamethasone (BiRd) versus lenalidomideâ€lowâ€dose dexamethasone (Rd) for newly diagnosed myeloma. American Journal of Hematology, 2010, 85, 664-669.	2.0	49
375	A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?. Haematologica, 2013, 98, 988-992.	1.7	49
376	Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer Journal, 2016, 6, e486-e486.	2.8	49
377	Efficacy of VDT PACEâ€like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	2.0	49
378	Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 1-2.	1.4	49

#	Article	IF	Citations
379	Bone marrow angiogenesis in multiple myeloma: effect of therapy. British Journal of Haematology, 2002, 119, 665-671.	1.2	48
380	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology, 2012, 156, 326-333.	1.2	48
381	Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. Histopathology, 2016, 68, 648-656.	1.6	48
382	Two types of amyloidosis presenting in a single patient: a case series. Blood Cancer Journal, 2019, 9, 30.	2.8	48
383	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	1.3	48
384	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Biology of Blood and Marrow Transplantation, 2017, 23, 598-605.	2.0	47
385	Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer Journal, 2018, 8, 96.	2.8	47
386	A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia, 2005, 19, 118-125.	3.3	46
387	Kidney Involvement of Patients with WaldenstrÃ¶m Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1037-1046.	2.2	46
388	The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood, 2009, 114, 2617-2618.	0.6	45
389	Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17â€‰315 patients. Leukemia, 2013, 27, 1391-1393.	3.3	45
390	Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. British Journal of Haematology, 2014, 165, 39-48.	1.2	45
391	Induction therapy preâ€autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	2.0	45
392	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Annals of Medicine, 2017, 49, 545-551.	1.5	45
393	IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	2.0	45
394	Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777. Blood, 2015, 126, 25-25.	0.6	45
395	Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood, 2005, 106, 3353-3357.	0.6	44
396	Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia, 2010, 24, 1406-1411.	3.3	44

#	Article	IF	Citations
397	Screening Method for M-Proteins in Serum Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. Clinical Chemistry, 2016, 62, 1345-1352.	1.5	44
398	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia, 2018, 32, 729-735.	3.3	44
399	A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leukemia and Lymphoma, 2006, 47, 39-42.	0.6	43
400	Systemic Immunoglobulin Light Chain Amyloidosisâ€“Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	1.4	43
401	N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. Leukemia, 2020, 34, 2749-2753.	3.3	43
402	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	3.3	43
403	High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplantation, 2001, 28, 381-385.	1.3	42
404	Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood, 2010, 115, 2348-2353.	0.6	42
405	Nerve pathologic features differentiate POEMS syndrome from CIDP. Acta Neuropathologica Communications, 2016, 4, 116.	2.4	42
406	A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood, 2018, 132, 670-672.	0.6	42
407	Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clinical Cancer Research, 2005, 11, 1210-8.	3.2	42
408	Treatment of poems syndrome. Current Treatment Options in Oncology, 2004, 5, 249-257.	1.3	41
409	Identification of Two Groups of Smoldering Multiple Myeloma Patients Who Are Either High or Low Producers of Interleukin-1. Journal of Interferon and Cytokine Research, 2006, 26, 83-95.	0.5	41
410	Betaâ€blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. American Journal of Hematology, 2017, 92, 50-55.	2.0	41
411	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	2.5	41
412	Ibrutinib monotherapy outside of clinical trial setting in WaldenstrÃ¶m macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	1.2	41
413	Relationship Between Depth of Response and Outcome in Multiple Myeloma. Journal of Clinical Oncology, 2007, 25, 4933-4937.	0.8	40
414	Laboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities. American Journal of Clinical Pathology, 2012, 138, 609-613.	0.4	40

#	Article	IF	Citations
415	Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematology,the, 2014, 1, e28-e36.	2.2	40
416	Tenâ€year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology, 2019, 187, 588-594.	1.2	40
417	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	3.3	40
418	Artificial Intelligenceâ€“Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 2768-2778.	1.4	40
419	Castleman Disease. , 2008, 142, 293-330.		40
420	Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology, 2007, 69, 1136-1141.	1.5	39
421	Serum Uric Acid: Novel Prognostic Factor in Primary Systemic Amyloidosis. Mayo Clinic Proceedings, 2008, 83, 297-303.	1.4	39
422	Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. American Journal of Hematology, 2010, 85, 431-434.	2.0	39
423	Dexamethasone-Induced Oxidative Stress Enhances Myeloma Cell Radiosensitization While Sparing Normal Bone Marrow Hematopoiesis. Neoplasia, 2010, 12, 980-992.	2.3	39
424	Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Annals of Hematology, 2011, 90, 101-106.	0.8	39
425	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer Journal, 2017, 7, e528-e528.	2.8	39
426	Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf (Pts) Ineligible For Stem Cell Transplantation (SCT). Blood, 2013, 122, 2-2.	0.6	39
427	Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chainâ€“Associated Amyloidosis after Autologous Stem Cell Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 440-444.	2.2	38
428	Cutaneous manifestations in patients with POEMS syndrome. International Journal of Dermatology, 2013, 52, 1349-1356.	0.5	38
429	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. American Journal of Hematology, 2015, 90, 981-985.	2.0	38
430	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer Journal, 2016, 6, e512-e512.	2.8	38
431	Myelomatous Involvement of the Central Nervous System. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 644-654.	0.2	38
432	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	2.8	38

#	Article	IF	Citations
433	Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. American Journal of Cardiology, 2001, 88, 813-815.	0.7	37
434	Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood, 2006, 107, 4063-4070.	0.6	37
435	IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering WaldenstrÃ¶m's Macroglobulinemia (SWM). Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 74-76.	0.2	37
436	Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1233-1237.	2.0	37
437	Phenotyping Polyclonal Kappa and Lambda Light Chain Molecular Mass Distributions in Patient Serum Using Mass Spectrometry. Journal of Proteome Research, 2014, 13, 5198-5205.	1.8	37
438	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin lightâ€chain amyloidosis. Cancer, 2016, 122, 2197-2205.	2.0	37
439	Enhancing the Râ€ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	2.0	37
440	High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis. New England Journal of Medicine, 2008, 358, 91-93.	13.9	36
441	Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification. Biology of Blood and Marrow Transplantation, 2014, 20, 222-228.	2.0	36
442	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leukemia and Lymphoma, 2015, 56, 3357-3364.	0.6	36
443	Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. Blood Cancer Journal, 2015, 5, e363-e363.	2.8	36
444	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. American Journal of Hematology, 2019, 94, 1020-1026.	2.0	36
445	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019, 33, 527-531.	3.3	36
446	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer Journal, 2020, 10, 55.	2.8	36
447	Free light chains in plasma of patients with light chain amyloidosis and nonâ€amyloid light chain deposition disease. High proportion and heterogeneity of disulfideâ€linked monoclonal free light chains as pathogenic features of amyloid disease. British Journal of Haematology, 2009, 144, 705-715.	1.2	35
448	Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood, 2011, 118, 2985-2987.	0.6	35
449	Computed tomography assessment of bone lesions in patients with POEMS syndrome. European Radiology, 2015, 25, 497-504.	2.3	35
450	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology, 2020, 95, 497-502.	2.0	35

#	Article	IF	Citations
451	Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. American Journal of Kidney Diseases, 2005, 45, 102-111.	2.1	34
452	Doppler Myocardial Imaging Compared to Standard Two-Dimensional and Doppler Echocardiography for Assessment of Diastolic Function in Patients With Systemic Amyloidosis. Journal of the American Society of Echocardiography, 2009, 22, 290-298.	1.2	34
453	Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia, 2010, 24, 1498-1505.	3.3	34
454	Localized insulinâ€derived amyloidosis: A potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. American Journal of Hematology, 2012, 87, E131-2.	2.0	34
455	Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. American Journal of Hematology, 2013, 88, 375-378.	2.0	34
456	Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplantation, 2015, 50, 1513-1518.	1.3	34
457	MASSâ€FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. American Journal of Hematology, 2018, 93, E368-E370.	2.0	34
458	Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. Blood Cancer Journal, 2019, 9, 72.	2.8	34
459	Monoclonal gammopathies of clinical significance. Hematology American Society of Hematology Education Program, 2020, 2020, 380-388.	0.9	34
460	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	1.4	34
461	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood, 2019, 134, 139-139.	0.6	34
462	Hepatic amyloidosis resulting from deposition of the apolipoprotein A-I variant Leu75Pro. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 215-223.	1.4	33
463	Response to Rituximab in Patients with Type II Cryoglobulinemia. Clinical Lymphoma and Myeloma, 2006, 7, 140-144.	1.4	33
464	Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. Leukemia, 2012, 26, 2286-2296.	3.3	33
465	New Cancers after Autotransplantations for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 738-745.	2.0	33
466	Impact of MYD88^{L265P} mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	2.0	33
467	High-Dose Chemotherapy with Autotransplantation in AL Amyloidosis: A Flawed Meta-analysis. Biology of Blood and Marrow Transplantation, 2010, 16, 138-140.	2.0	32
468	Long-Term Follow-Up of Patients with Monoclonal Gammopathy of Undetermined Significance after Kidney Transplantation. American Journal of Nephrology, 2012, 35, 365-371.	1.4	32

#	Article	IF	Citations
469	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. American Journal of Hematology, 2014, 89, 1051-1054.	2.0	32
470	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia, 2016, 30, 1079-1085.	3.3	32
471	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	3.2	32
472	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	1.4	32
473	Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple Myeloma. Leukemia and Lymphoma, 1999, 35, 599-605.	0.6	31
474	Ploidy status rarely changes in myeloma patients at disease progression. Leukemia Research, 2006, 30, 266-271.	0.4	31
475	Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplantation, 2012, 47, 831-837.	1.3	31
476	Soluble suppression of tumorigenicity 2 (s<scp>ST</scp>2), but not galactinâ€3, adds to prognostication in patients with systemic <scp>AL</scp> amyloidosis independent of <scp>NT</scp>â€pro<scp>BNP</scp> and troponin <scp>T</scp>. American Journal of Hematology, 2015, 90, 524-528.	2.0	31
477	Monitoring free light chains in serum using mass spectrometry. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1073-83.	1.4	31
478	Clinical relevance of pulmonary amyloidosis: an analysis of 76 autopsy-derived cases. European Respiratory Journal, 2017, 49, 1602313.	3.1	31
479	Attitudes about when and how to treat patients with AL amyloidosis: an international survey. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 213-216.	1.4	31
480	OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS. Retina, 2018, 38, 1371-1376.	1.0	31
481	Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry. Clinical Chemistry, 2019, 65, 1015-1022.	1.5	31
482	Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.. Blood, 2006, 108, 798-798.	0.6	31
483	Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplantation, 2003, 32, 587-592.	1.3	30
484	Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. Neurology, 2010, 74, 913-918.	1.5	30
485	Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT. Bone Marrow Transplantation, 2013, 48, 1543-1547.	1.3	30
486	Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia, 2013, 27, 2062-2066.	3.3	30

#	Article	IF	Citations
487	<scp>AT</scp>â€101 downregulates <scp>BCL</scp>2 and <scp>MCL</scp>1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and <scp>W</scp>aldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2014, 164, 352-365.	1.2	30
488	Advanced Cardiac Amyloidosis Associated withÂNormal Interventricular Septal Thickness: AnÂUncommon Presentation of Infiltrative Cardiomyopathy. Journal of the American Society of Echocardiography, 2014, 27, 440-447.	1.2	30
489	Thrombocytosis distinguishes POEMS syndrome from chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2015, 52, 658-659.	1.0	30
490	Clinical spectrum of Castleman diseaseâ€“associated neuropathy. Neurology, 2016, 87, 2457-2462.	1.5	30
491	Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.	2.0	30
492	Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer Journal, 2016, 6, e401-e401.	2.8	30
493	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia, 2017, 31, 92-99.	3.3	30
494	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. Bone Marrow Transplantation, 2017, 52, 1126-1132.	1.3	30
495	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplantation, 2017, 52, 34-40.	1.3	30
496	The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry. Kidney International, 2019, 96, 1005-1009.	2.6	30
497	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	2.8	30
498	Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 458-463.	0.2	29
499	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica, 2017, 102, 1439-1445.	1.7	29
500	Fifty-Year Incidence of WaldenstrÃ¶m Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. Mayo Clinic Proceedings, 2018, 93, 739-746.	1.4	29
501	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	2.8	29
502	Monoclonal gammopathyâ€associated thrombotic microangiopathy. American Journal of Hematology, 2019, 94, E250-E253.	2.0	29
503	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	3.3	29
504	A randomized phase 3 study of ixazomibâ€“dexamethasone versus physicianâ€™s choice in relapsed or refractory AL amyloidosis. Leukemia, 2022, 36, 225-235.	3.3	29

#	Article	IF	Citations
505	Natural history of thromboembolism in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 31-36.	1.4	28
506	Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 263-268.	1.4	28
507	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	3.3	28
508	POEMS Syndrome. Hematology/Oncology Clinics of North America, 2018, 32, 119-139.	0.9	28
509	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Advances, 2019, 3, 744-750.	2.5	28
510	Primary systemic amyloidosis in patients with WaldenstrÃ¶m macroglobulinemia. Leukemia, 2019, 33, 790-794.	3.3	28
511	New developments in diagnosis, risk assessment and management in systemic amyloidosis. Blood Reviews, 2020, 40, 100636.	2.8	28
512	Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab. Clinical Chemistry and Laboratory Medicine, 2021, 59, 155-163.	1.4	28
513	â€œReal-lifeâ€•data of the efficacy and safety of belantamab mafodotin in relapsed multiple myelomaâ€”the Mayo Clinic experience. Blood Cancer Journal, 2021, 11, 196.	2.8	28
514	Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype. Journal of the American Society of Nephrology: JASN, 2017, 28, 431-438.	3.0	27
515	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia, 2018, 32, 712-718.	3.3	27
516	Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin. Journal of Clinical Oncology, 2019, 37, 171-173.	0.8	27
517	Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. Blood, 2019, 133, 763-766.	0.6	27
518	Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Cancer Gene Therapy, 2012, 19, 202-211.	2.2	26
519	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer Journal, 2020, 10, 20.	2.8	26
520	Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis. JACC: Heart Failure, 2021, 9, 736-746.	1.9	26
521	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. Blood, 2012, 120, 3138-3138.	0.6	26
522	Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS. European Journal of Haematology, 2012, 88, 549-550.	1.1	25

#	Article	IF	Citations
523	Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia, 2015, 29, 2033-2038.	3.3	25
524	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology Dialysis Transplantation, 2016, 31, 1284-1289.	0.4	25
525	Dexamethasone, rituximab and cyclophosphamide for relapsedÂand/or refractory and treatmentâ€naÃ¯ve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	1.2	25
526	Efficacy of daratumumabâ€based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	2.0	25
527	Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects. EJNMMI Research, 2017, 7, 90.	1.1	25
528	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	1.4	25
529	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer Journal, 2021, 11, 50.	2.8	25
530	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). Blood, 2014, 124, 304-304.	0.6	25
531	'Hypersynchronisation' by tissue velocity imaging in patients with cardiac amyloidosis. Heart, 2008, 95, 234-240.	1.2	24
532	Longâ€term results of singleâ€agent thalidomide as initial therapy for asymptomatic (smoldering or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.0	24
533	Thermal Stability Threshold for Amyloid Formation in Light Chain Amyloidosis. International Journal of Molecular Sciences, 2013, 14, 22604-22617.	1.8	24
534	Frequencies and geographic distributions of genetic mutations in transthyretinâ€and nonâ€transthyretinâ€related familial amyloidosis. Clinical Genetics, 2015, 88, 396-400.	1.0	24
535	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 447-452.	0.2	24
536	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. American Journal of Hematology, 2017, 92, 549-554.	2.0	24
537	Predictors of symptomatic hyperviscosity in WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	2.0	24
538	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer Journal, 2020, 10, 41.	2.8	24
539	Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 8-13.	1.4	24
540	Symptomatic cryoglobulinemia. Current Treatment Options in Oncology, 2000, 1, 105-118.	1.3	23

#	Article	IF	Citations
541	Bortezomib for Myeloma â€" Much Ado about Something. New England Journal of Medicine, 2005, 352, 2546-2548.	13.9	23
542	The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma. Leukemia and Lymphoma, 2005, 46, 1287-1294.	0.6	23
543	Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death. European Heart Journal, 2010, 31, 1538-1538.	1.0	23
544	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. European Journal of Haematology, 2014, 92, 485-490.	1.1	23
545	Immunoglobulin Light Chain Systemic Amyloidosis. Cancer Treatment and Research, 2016, 169, 273-318.	0.2	23
546	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances, 2018, 2, 769-776.	2.5	23
547	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2018, 2, 3149-3154.	2.5	23
548	Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). Biology of Blood and Marrow Transplantation, 2008, 14, 6-11.	2.0	22
549	Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. Clinical Chemistry and Laboratory Medicine, 2008, 46, 335-41.	1.4	22
550	A Phase II study of ¹⁵³Smâ€EDTMP and highâ€dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. American Journal of Hematology, 2010, 85, 409-413.	2.0	22
551	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research, 2016, 44, 32-39.	0.4	22
552	Myocardial Stiffness by Intrinsic Cardiac Elastography in Patients with Amyloidosis: Comparison with Chamber Stiffness and Global Longitudinal Strain. Journal of the American Society of Echocardiography, 2019, 32, 958-968.e4.	1.2	22
553	Comparative analysis of staging systems in AL amyloidosis. Leukemia, 2019, 33, 811-814.	3.3	22
554	Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	22
555	Treatment options for POEMS syndrome. Expert Opinion on Pharmacotherapy, 2005, 6, 945-953.	0.9	21
556	High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Review of Anticancer Therapy, 2006, 6, 343-360.	1.1	21
557	Utility of Doppler Myocardial Imaging, Cardiac Biomarkers, and Clonal Immunoglobulin Genes to Assess Left Ventricular Performance and Stratify Risk Following Peripheral Blood Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis (AL). Journal of the American Society of Echocardiography, 2011, 24, 444-454.e2.	1.2	21
558	A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment. Muscle and Nerve, 2012, 46, 964-970.	1.0	21

#	Article	IF	Citations
559	Implications of continued response after autologous stem cell transplantation for multiple myeloma. Blood, 2013, 122, 1746-1749.	0.6	21
560	Costâ€effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. Clinical Transplantation, 2014, 28, 1084-1091.	0.8	21
561	Apolipoprotein A-IVâ€“Associated Cardiac Amyloidosis. Journal of the American College of Cardiology, 2017, 69, 2248-2249.	1.2	21
562	Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation. Progress in Transplantation, 2017, 27, 246-250.	0.4	21
563	Delineation of the timing of second-line therapy postâ€“autologous stem cell transplant in patients with AL amyloidosis. Blood, 2017, 130, 1578-1584.	0.6	21
564	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2127-2132.	2.0	21
565	Classification of Plasma Cell Disorders by 21 Tesla Fourier Transform Ion Cyclotron Resonance Top-Down and Middle-Down MS/MS Analysis of Monoclonal Immunoglobulin Light Chains in Human Serum. Analytical Chemistry, 2019, 91, 3263-3269.	3.2	21
566	Implications of detecting serum monoclonal protein by MASSâ€fix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	1.2	21
567	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. American Journal of Hematology, 2021, 96, 1131-1136.	2.0	21
568	Increased Utilization of Virtual Visits and Electronic Approaches in Clinical Research During the COVID-19 Pandemic and Thereafter. Mayo Clinic Proceedings, 2021, 96, 2332-2341.	1.4	21
569	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC: CardioOncology, 2021, 3, 537-546.	1.7	21
570	Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation. Annals of Hematology, 2007, 86, 303-306.	0.8	20
571	Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplantation, 2008, 41, 1013-1019.	1.3	20
572	Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. British Journal of Haematology, 2008, 141, 205-211.	1.2	20
573	Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. Leukemia and Lymphoma, 2008, 49, 1724-1730.	0.6	20
574	Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. , 2008, , CD006828.		20
575	Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with lightâ€chain amyloidosis. American Journal of Hematology, 2012, 87, 51-54.	2.0	20
576	Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. Bone Marrow Transplantation, 2014, 49, 201-205.	1.3	20

#	Article	IF	Citations
577	Elevation of Serum Immunoglobulin Free Light Chains During the Preclinical Period of Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 181-187.	1.0	20
578	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e493-e499.	0.2	20
579	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2019, 25, e108-e111.	2.0	20
580	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia, 2019, 33, 730-738.	3.3	20
581	A Proteomic Atlas of CardiacÂAmyloid Plaques. JACC: CardioOncology, 2020, 2, 632-643.	1.7	20
582	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances, 2020, 4, 2236-2244.	2.5	20
583	Myeloma in Elderly Patients: When Less Is More and More Is More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 575-585.	1.8	20
584	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. Transplantation and Cellular Therapy, 2022, 28, 473-482.	0.6	20
585	Acute neuropathies after peripheral blood stem cell and bone marrow transplantation. Muscle and Nerve, 2003, 28, 733-736.	1.0	19
586	Autologous stem cell transplantation and IgM amyloidosis. Leukemia and Lymphoma, 2006, 47, 1006-1012.	0.6	19
587	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leukemia and Lymphoma, 2015, 56, 1723-1726.	0.6	19
588	Myeloma: management of the newly diagnosed high-risk patient. Hematology American Society of Hematology Education Program, 2016, 2016, 485-494.	0.9	19
589	HLA polymorphism and risk of multiple myeloma. Leukemia, 2016, 30, 2260-2264.	3.3	19
590	Utility and prognostic value of ¹⁸Fâ€FDG positron emission tomographyâ€computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	2.0	19
591	Characteristics of late transplantâ€associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179.	2.0	19
592	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. Blood, 2010, 116, 1364-1364.	0.6	19
593	Comprehensive Assessment of Potential Multiple Myeloma Immunoglobulin Heavy Chain V-D-J Intraclonal Variation Using Massively Parallel Pyrosequencing. Oncotarget, 2012, 3, 502-513.	0.8	19
594	Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). Blood Cancer Journal, 2022, 12, 27.	2.8	19

#	Article	IF	Citations
595	Novel Analysis of Clonal Diversification in Blood B Cell and Bone Marrow Plasma Cell Clones in Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Immunology, 2007, 27, 69-87.	2.0	18
596	Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. American Journal of Hematology, 2012, 87, 1-4.	2.0	18
597	Exploring the amyloid proteome in immunoglobulinâ€derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry. American Journal of Hematology, 2013, 88, 577-580.	2.0	18
598	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. American Journal of Hematology, 2015, 90, 888-891.	2.0	18
599	Patient-reported Outcomes for Multicentric Castlemanâ€™s Disease in a Randomized, Placebo-controlled Study of Siltuximab. Patient, 2015, 8, 207-216.	1.1	18
600	Ixazomibâ€induced thrombotic microangiopathy. American Journal of Hematology, 2017, 92, E53-E55.	2.0	18
601	Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis. Transplantation, 2018, 102, 1909-1913.	0.5	18
602	Aortic valve replacement in patients with amyloidosis. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 98-103.	0.4	18
603	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. American Journal of Hematology, 2019, 94, 306-311.	2.0	18
604	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	2.8	18
605	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. American Journal of Hematology, 2020, 95, 1553-1561.	2.0	18
606	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer Journal, 2020, 10, 4.	2.8	18
607	Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer Journal, 2021, 11, 120.	2.8	18
608	A novel report of cigâ€FISH and cytogenetics in POEMS syndrome. American Journal of Hematology, 2008, 83, 840-841.	2.0	17
609	Effect of Tissue Shipping on Plasma Cell Isolation, Viability, and RNA Integrity in the Context of a Centralized Good Laboratory Practiceâ€“Certified Tissue Banking Facility. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 666-673.	1.1	17
610	Ushering in a new era for POEMS. Blood, 2011, 117, 6405-6406.	0.6	17
611	Immunoglobulin D amyloidosis: a distinct entity. Blood, 2012, 119, 44-48.	0.6	17
612	Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance and Smoldering WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 184-186.	0.2	17

#	Article	IF	Citations
613	Multiple myeloma after kidney transplantation. Clinical Transplantation, 2015, 29, 76-84.	0.8	17
614	Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplantation, 2016, 51, 1156-1158.	1.3	17
615	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood, 2016, 127, 2936-2938.	0.6	17
616	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. British Journal of Haematology, 2019, 185, 701-707.	1.2	17
617	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. American Journal of Hematology, 2019, 94, E141-E143.	2.0	17
618	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. American Journal of Hematology, 2020, 95, 1280-1287.	2.0	17
619	Specificity of Serum and Urine Protein Electrophoresis for the Diagnosis of Monoclonal Gammopathies. Clinical Chemistry, 2010, 56, 1899-1900.	1.5	16
620	SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. Bone Marrow Transplantation, 2011, 46, 956-961.	1.3	16
621	Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2016, 22, 796-801.	2.0	16
622	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2017, 58, 308-315.	0.6	16
623	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. American Journal of Hematology, 2017, 92, 435-440.	2.0	16
624	Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept. American Journal of Hematology, 2017, 92, 536-541.	2.0	16
625	Myeloma in Elderly Patients: When Less Is More and More Is More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 575-585.	1.8	16
626	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Mayo Clinic Proceedings, 2018, 93, 56-58.	1.4	16
627	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer Journal, 2018, 8, 106.	2.8	16
628	MRI feature tracking strain is prognostic for all-cause mortality in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 101-108.	1.4	16
629	Heavy Chain Fibrillary Glomerulonephritis: A Case Report. American Journal of Kidney Diseases, 2019, 74, 276-280.	2.1	16
630	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clinic Proceedings, 2021, 96, 677-687.	1.4	16

#	Article	IF	Citations
631	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	1.3	16
632	Combination Therapy with CC-5013 (Lenalidomide; Revlimidâ„¢) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. Blood, 2004, 104, 331-331.	0.6	16
633	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients. Blood, 2012, 120, 201-201.	0.6	16
634	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. Blood, 2012, 120, 2973-2973.	0.6	16
635	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. Mayo Clinic Proceedings, 2019, 94, 455-464.	1.4	16
636	Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. Mayo Clinic Proceedings, 2022, 97, 294-307.	1.4	16
637	Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Science, 2007, 98, 1035-1040.	1.7	15
638	Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies. Leukemia, 2012, 26, 1119-1122.	3.3	15
639	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. Journal of Internal Medicine, 2017, 281, 611-619.	2.7	15
640	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology, 2017, 178, 888-895.	1.2	15
641	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. British Journal of Haematology, 2018, 182, 71-77.	1.2	15
642	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	2.0	15
643	Increased Myocardial Stiffness Detected by Intrinsic Cardiac Elastography in Patients With Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 375-377.	2.3	15
644	Revisiting complete response in light chain amyloidosis. Leukemia, 2020, 34, 1472-1475.	3.3	15
645	Free Light Chain Assay Drift: Potential for Misdiagnosis?. journal of applied laboratory medicine, The, 2020, 5, 1411-1413.	0.6	15
646	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. American Journal of Hematology, 2020, 95, E222-E225.	2.0	15
647	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.2	15
648	Autologous stem cell transplantation for multiple myeloma patients aged â‰¥ 75 treated with novel agents. Bone Marrow Transplantation, 2021, 56, 1144-1150.	1.3	15

#	Article	IF	Citations
649	Peripheral blood stem cell transplant (PBSCT) in a large series of patients with poems syndrome. Biology of Blood and Marrow Transplantation, 2004, 10, 14-15.	2.0	14
650	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 889-894.	2.0	14
651	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 2360-2364.	2.0	14
652	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. American Journal of Hematology, 2019, 94, 1066-1071.	2.0	14
653	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	2.0	14
654	Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life. Blood, 2019, 134, 794-794.	0.6	14
655	Quantitative analysis of clonal bone marrow CD19+ B cells: Use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis. Clinical Immunology, 2006, 120, 106-120.	1.4	13
656	Molecular analysis of immunoglobulin genes reveals frequent clonal relatedness in double monoclonal gammopathies. Blood Cancer Journal, 2013, 3, e112-e112.	2.8	13
657	Pulmonary morbidity improves after autologous stem cell transplantation in POEMS syndrome. Respiratory Medicine, 2015, 109, 122-130.	1.3	13
658	Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. Leukemia, 2016, 30, 995-998.	3.3	13
659	A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. Bone Marrow Transplantation, 2017, 52, 1372-1377.	1.3	13
660	Pomalidomideâ€“dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia, 2018, 32, 719-728.	3.3	13
661	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. American Journal of Hematology, 2019, 94, E117-E120.	2.0	13
662	Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. Blood Cancer Journal, 2020, 10, 87.	2.8	13
663	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney International, 2021, 99, 707-715.	2.6	13
664	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as firstâ€line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	2.0	13
665	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Advances, 2021, 5, 2753-2759.	2.5	13
666	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 864-864.	0.6	13

#	Article	IF	Citations
667	Proteome Of Amyloidosis: Mayo Clinic Experience In 4139 Cases. Blood, 2013, 122, 1900-1900.	0.6	13
668	Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. Blood, 2010, 116, 3554-3554.	0.6	13
669	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Advances, 2022, 6, 2763-2772.	2.5	13
670	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. Blood Cancer Journal, 2022, 12, 67.	2.8	13
671	Increased prevalence of light chain monoclonal gammopathy of undetermined significance (<scp>LC</scp>â€<scp>MGUS</scp>) in firstâ€degree relatives of individuals with multiple myeloma. British Journal of Haematology, 2012, 157, 472-475.	1.2	12
672	Treatment tradeâ€offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. Cancer, 2013, 119, 4308-4315.	2.0	12
673	The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. Leukemia, 2018, 32, 1243-1246.	3.3	12
674	Substratification of patients with newly diagnosed standardâ€risk multiple myeloma. British Journal of Haematology, 2019, 185, 254-260.	1.2	12
675	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia, 2019, 33, 1273-1277.	3.3	12
676	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	2.8	12
677	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	2.0	12
678	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving postâ€autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology, 2021, 96, E157-E162.	2.0	12
679	Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 377-387.	1.4	12
680	Assessment of fixedâ€duration therapies for treatmentâ€naÃ¯ve <scp>WaldenstrÃ¶m</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	2.0	12
681	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. Blood, 2013, 122, 407-407.	0.6	12
682	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia, 2022, 36, 873-876.	3.3	12
683	Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement. Kidney International, 2005, 68, 1464-1471.	2.6	11
684	Screening Algorithms for Monoclonal Gammopathies. Clinical Chemistry, 2008, 54, 1753-1755.	1.5	11

#	Article	IF	Citations
685	Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy. Leukemia and Lymphoma, 2012, 53, 1057-1061.	0.6	11
686	Evaluation of pretransplant factors predicting cardiac dysfunction following highâ€dose melphalan conditioning and autologous peripheral blood stem cell transplantation. European Journal of Haematology, 2012, 89, 228-235.	1.1	11
687	18F-Florbetapir and 18F-FDG PET/CT in Systemic Immunoglobulin Light Chain Amyloidosis Involving the Peripheral Nerves. Clinical Nuclear Medicine, 2016, 41, e115-e117.	0.7	11
688	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). American Journal of Hematology, 2018, 93, 17-22.	2.0	11
689	Magnetic Resonance Elastography of Liver in Light Chain Amyloidosis. Journal of Clinical Medicine, 2019, 8, 739.	1.0	11
690	Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. Blood Cancer Journal, 2019, 9, 49.	2.8	11
691	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	2.0	11
692	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet Journal of Rare Diseases, 2021, 16, 204.	1.2	11
693	Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials. Oncology, 2012, 26, 152-61.	0.4	11
694	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. Blood Advances, 2022, , .	2.5	11
695	Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). Bone Marrow Transplantation, 2007, 40, 989-993.	1.3	10
696	Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplantation, 2008, 42, 259-264.	1.3	10
697	Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 2010, 148, 853-858.	1.2	10
698	A Risk Adapted Approach Utilizing Plerixafor In Autologous Peripheral Blood Stem Cell Mobilization. Biology of Blood and Marrow Transplantation, 2010, 16, S197-S198.	2.0	10
699	High prevalence of polyclonal hypergammaâ€globulinemia in adult males in Ghana, Africa. American Journal of Hematology, 2011, 86, 554-558.	2.0	10
700	Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia, 2012, 26, 839-841.	3.3	10
701	Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. British Journal of Haematology, 2015, 168, 82-93.	1.2	10
702	Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 349-357.e2.	0.2	10

#	Article	IF	Citations
703	Validation of a prognostic score for patients with POEMS syndrome: a mayo clinic cohort. Leukemia, 2017, 31, 1251-1251.	3.3	10
704	First report of MYD88^{L265P} somatic mutation in IgM-associated light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 42-43.	1.4	10
705	Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology, 2017, 179, 170-172.	1.2	10
706	MRI of pathology-proven peripheral nerve amyloidosis. Skeletal Radiology, 2017, 46, 65-73.	1.2	10
707	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica, 2018, 103, 1229-1234.	1.7	10
708	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. American Journal of Hematology, 2020, 95, E8-E10.	2.0	10
709	The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 111-118.	1.4	10
710	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer Journal, 2021, 11, 26.	2.8	10
711	Chemotherapyâ€based approach is the preferred treatment for sporadic lateâ€onset nemaline myopathy with a monoclonal protein. International Journal of Cancer, 2021, 148, 2807-2814.	2.3	10
712	ASSOCIATION BETWEEN CHOROIDAL CHARACTERISTICS AND SYSTEMIC SEVERITY IN AMYLOIDOSIS. Retina, 2021, 41, 1037-1046.	1.0	10
713	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	0.6	10
714	Amyloidosis and POEMS syndrome. Expert Opinion on Pharmacotherapy, 2010, 11, 1501-1514.	0.9	9
715	Chronic myopathy due to immunoglobulin light chain amyloidosis. Molecular Genetics and Metabolism, 2013, 108, 249-254.	0.5	9
716	Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagulation and Fibrinolysis, 2016, 27, 101-108.	0.5	9
717	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica, 2016, 101, 1102-1109.	1.7	9
718	Blink R1 latency utility in diagnosis and treatment assessment of polyradiculoneuropathyâ€organomegalyâ€endocrinopathyâ€monoclonal proteinâ€skin changes and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle and Nerve, 2018, 57, E8-E13.	1.0	9
719	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 101-102.	1.4	9
720	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clinic Proceedings, 2019, 94, 1834-1839.	1.4	9

#	Article	IF	Citations
721	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biology of Blood and Marrow Transplantation, 2019, 25, 1520-1525.	2.0	9
722	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. Bone Marrow Transplantation, 2019, 54, 1775-1779.	1.3	9
723	The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. Orphanet Journal of Rare Diseases, 2020, 15, 268.	1.2	9
724	Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Advances, 2021, 5, 1029-1036.	2.5	9
725	Clearing drug interferences in myeloma treatment using mass spectrometry. Clinical Biochemistry, 2021, 92, 61-66.	0.8	9
726	The Clinical Impact of Proteomics in Amyloid Typing. Mayo Clinic Proceedings, 2021, 96, 1122-1127.	1.4	9
727	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)â€“Associated Lesions: A Case Series. American Journal of Kidney Diseases, 2022, 79, 202-216.	2.1	9
728	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 451-460.e2.	0.2	9
729	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer Journal, 2021, 11, 158.	2.8	9
730	The Natural History of Smoldering (Asymptomatic) Multiple Myeloma.. Blood, 2005, 106, 3396-3396.	0.6	9
731	Single Agent Bortezomib Is Associated with a High Response Rate in Patients with High Risk Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02).. Blood, 2006, 108, 3527-3527.	0.6	9
732	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. Blood, 2013, 122, 2151-2151.	0.6	9
733	Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. European Journal of Haematology, 2010, 85, 200-208.	1.1	8
734	Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. Leukemia, 2011, 25, 1195-1197.	3.3	8
735	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer Journal, 2017, 7, e569-e569.	2.8	8
736	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	3.3	8
737	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 155-161.	1.3	8
738	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.	2.0	8

#	Article	IF	Citations
739	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.2	8
740	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137.	1.3	8
741	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	2.8	8
742	CNV Radar: an improved method for somatic copy number alteration characterization in oncology. BMC Bioinformatics, 2020, 21, 98.	1.2	8
743	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Advances, 2020, 4, 322-326.	2.5	8
744	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	3.3	8
745	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. Leukemia, 2021, 35, 3604-3607.	3.3	8
746	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	0.7	8
747	Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort. American Journal of Hematology, 2021, 96, 446-454.	2.0	8
748	Low Dose Single Agent Thalidomide Is Tolerated in Patients with Primary Systemic Amyloidosis, but Responses Are Limited.. Blood, 2004, 104, 4920-4920.	0.6	8
749	A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis.. Blood, 2009, 114, 3853-3853.	0.6	8
750	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood, 2015, 126, 3050-3050.	0.6	8
751	Rituximab-based maintenance therapy in WaldenstrÃ¶m macroglobulinemia: A case control study.. Journal of Clinical Oncology, 2019, 37, 7559-7559.	0.8	8
752	The Depth of Renal Response Strongly Predicts Overall Surival in Patients with AL Amyloidosis. Blood, 2011, 118, 2868-2868.	0.6	8
753	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	2.8	8
754	WaldenstrÃ¶m Macroglobulinemia in the Very Elderly (â‰¥75 years):Clinical Characteristics and Outcomes. Blood, 2020, 136, 44-45.	0.6	8
755	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio â‰¥100. Leukemia, 2022, 36, 1429-1431.	3.3	8
756	Enhancing the therapeutic index of radiation in multiple myeloma. Drug Discovery Today Disease Mechanisms, 2006, 3, 515-522.	0.8	7

#	Article	IF	Citations
757	Complications of Myeloma Therapy. Hematology/Oncology Clinics of North America, 2007, 21, 1247-1273.	0.9	7
758	Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cell Neoplasms. Biology of Blood and Marrow Transplantation, 2013, 19, 1395-1398.	2.0	7
759	Abnormal stress echocardiography findings in cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 124-131.	1.4	7
760	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation, 2019, 54, 442-447.	1.3	7
761	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Advances, 2019, 3, 1226-1229.	2.5	7
762	Characteristics of longâ€term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer, 2019, 125, 3574-3581.	2.0	7
763	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia, 2019, 33, 1268-1272.	3.3	7
764	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1077-1081.	1.3	7
765	The novel form of amyloidosis derived from EGFâ€containing fibulinâ€like extracellular matrix protein 1 (EFEMP1) preferentially affects the lower gastrointestinal tract of elderly females^a. Histopathology, 2021, 78, 459-463.	1.6	7
766	Nonâ€cardiac biopsy sites with high frequency of transthyretin amyloidosis. ESC Heart Failure, 2021, 8, 750-755.	1.4	7
767	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. Blood Advances, 2021, 5, 2101-2105.	2.5	7
768	Longer Term Follow up of the Ã, Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT). Blood, 2018, 132, 1992-1992.	0.6	7
769	Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma.. Blood, 2007, 110, 190-190.	0.6	7
770	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. Blood, 2012, 120, 3972-3972.	0.6	7
771	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. Blood, 2013, 122, 3210-3210.	0.6	7
772	Ixazomib-dexamethasone (Ixa-Dex) vs physicianâ€™s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. Journal of Clinical Oncology, 2020, 38, 8546-8546.	0.8	7
773	Importance of FISH genetics in light chain amyloidosis. Oncotarget, 2017, 8, 81735-81736.	0.8	7
774	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. , 2004, , 67-69.		7

#	Article	IF	Citations
775	Flow Cytometric Detection of Circulating Myeloma Cells Pretransplant in Patients with Multiple Myeloma: A Simple Risk Stratification System.. Blood, 2005, 106, 1164-1164.	0.6	7
776	Kidney Transplant Outcomes of Patients With Multiple Myeloma. Kidney International Reports, 2022, 7, 752-762.	0.4	7
777	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 2022, 36, 1426-1428.	3.3	7
778	Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Advances, 2023, 7, 909-917.	2.5	7
779	Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 175-183.	1.4	7
780	Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Cardiology and Therapy, 2022, 11, 393-405.	1.1	7
781	Primary cardiac amyloidosis with 20-year survival. Cardiovascular Pathology, 2006, 15, 331-335.	0.7	6
782	InÂvivoandinÂsilicostudies on single versus multiple transplants for multiple myeloma. Cancer Science, 2007, 98, 734-739.	1.7	6
783	Biology, treatment, and time. Blood, 2008, 112, 2999-3000.	0.6	6
784	Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia and Lymphoma, 2009, 50, 781-787.	0.6	6
785	Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplantation, 2010, 45, 490-497.	1.3	6
786	Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. Bone Marrow Transplantation, 2011, 46, 291-293.	1.3	6
787	Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma. Leukemia, 2014, 28, 455-457.	3.3	6
788	Renal risk and response in amyloidosis. Blood, 2014, 124, 2315-2316.	0.6	6
789	Clinical Course and Prognosis of Non-Secretory Multiple Myeloma. European Journal of Haematology, 2015, , n/a-n/a.	1.1	6
790	Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change. Blood Cancer Journal, 2021, 11, 29.	2.8	6
791	MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial.. Journal of Clinical Oncology, 2021, 39, 8009-8009.	0.8	6
792	Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study. Quality of Life Research, 2022, 31, 1083-1092.	1.5	6

#	Article	IF	Citations
793	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transplantation and Cellular Therapy, 2021, 27, 770.e1-770.e7.	0.6	6
794	Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma.. Blood, 2005, 106, 3475-3475.	0.6	6
795	High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels.. Blood, 2006, 108, 3514-3514.	0.6	6
796	Normalization of the Serum Free Light Chain (FLC) Ratio Is Associated with Superior Overall Survival among Myeloma Patients Achieving Immunofixation Negative State: Results Support Incorporation of Serum FLC Ratio in Stringent CR Definition.. Blood, 2008, 112, 1692-1692.	0.6	6
797	Immunoglobulin Variable Light Chain Restriction, Cytokine Expression and Plasma Cell-Stromal Cell Interactions in POEMS Syndrome Patients. Blood, 2008, 112, 2744-2744.	0.6	6
798	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). Blood, 2015, 126, 1774-1774.	0.6	6
799	Clinical Course and Prognosis of Smoldering (Asymptomatic) Waldenstromâ€™s Macroglobulinemia. Blood, 2008, 112, 2709-2709.	0.6	6
800	Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. Blood, 2010, 116, 3572-3572.	0.6	6
801	Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , .	2.0	6
802	The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis. Kidney International, 2022, 101, 152-163.	2.6	6
803	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. Bone Marrow Transplantation, 2022, 57, 803-809.	1.3	6
804	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. Blood Cancer Journal, 2022, 12, .	2.8	6
805	Is early, deep free light chain response really an adverse prognostic factor?. Blood, 2008, 111, 2490-2491.	0.6	5
806	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€“2. Mayo Clinic Proceedings, 2010, 85, 197-199.	1.4	5
807	A Cost Effective Analysis of a Risk-Adapted Algorithm for Plerixafor Use in Autologous Peripheral Blood Stem Cell Mobilization. Biology of Blood and Marrow Transplantation, 2011, 17, S159-S160.	2.0	5
808	Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias. Expert Review of Clinical Immunology, 2011, 7, 65-73.	1.3	5
809	Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. Blood Cancer Journal, 2015, 5, e294-e294.	2.8	5
810	Effect of Systemic Therapies on Outcomes following Vertebroplasty among Patients with Multiple Myeloma. American Journal of Neuroradiology, 2016, 37, 2400-2406.	1.2	5

#	Article	IF	Citations
811	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. American Journal of Hematology, 2017, 92, E507-E512.	2.0	5
812	Utility of the Serum Free Light Chain Assay in the Diagnosis of Light Chain Amyloidosis in Patients With Heart Failure. Mayo Clinic Proceedings, 2019, 94, 447-454.	1.4	5
813	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	1.3	5
814	Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement. Leukemia and Lymphoma, 2020, 61, 1752-1755.	0.6	5
815	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935.	1.3	5
816	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. Kidney International Reports, 2021, 6, 857-864.	0.4	5
817	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood, 2020, 136, 44-45.	0.6	5
818	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. Blood, 2005, 106, 781-781.	0.6	5
819	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. Blood, 2010, 116, 1964-1964.	0.6	5
820	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. Blood, 2015, 126, 4197-4197.	0.6	5
821	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. Blood, 2016, 128, 3337-3337.	0.6	5
822	Cytogenetic analysis using multiple myeloma targets in POEMS syndrome. Journal of Clinical Oncology, 2007, 25, 8116-8116.	0.8	5
823	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. Blood, 2010, 116, 2253-2253.	0.6	5
824	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. Blood, 2011, 118, 4120-4120.	0.6	5
825	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721.	0.6	5
826	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	2.0	5
827	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	2.0	5
828	Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 156-164.	1.4	5

#	Article	IF	Citations
829	The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease. Haematologica, 2023, 108, 207-218.	1.7	5
830	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances, 2022, 6, 3991-3995.	2.5	5
831	An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma. Leukemia, 2007, 21, 9-11.	3.3	4
832	Is there a future for auto-allo HSCT in multiple myeloma?. Lancet Oncology, The, 2011, 12, 1176-1177.	5.1	4
833	Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 137-138.	1.4	4
834	Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis. Leukemia, 2014, 28, 2273-2275.	3.3	4
835	Longâ€term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. American Journal of Hematology, 2014, 89, 302-305.	2.0	4
836	Accuracy of self-reported tobacco use status among hematopoietic SCT patients. Bone Marrow Transplantation, 2014, 49, 961-965.	1.3	4
837	Blaming the Right Fluorescent in Situ Hybridization. Journal of Clinical Oncology, 2015, 33, 3976-3976.	0.8	4
838	The yin and yang of autophagy in AL amyloidosis. Blood, 2017, 129, 2044-2045.	0.6	4
839	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 40-41.	1.4	4
840	Feasibility study of cardiac magnetic resonance elastography in cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 161-161.	1.4	4
841	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 183-188.	1.4	4
842	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation, 2018, 53, 326-333.	1.3	4
843	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2019, 60, 2960-2967.	0.6	4
844	Multiple Myeloma and Related Disorders. , 2020, , 1884-1910.e7.		4
845	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. American Journal of Hematology, 2020, 95, E60-E62.	2.0	4
846	Continuous lenalidomide and lowâ€dose dexamethasone in patients with transplantâ€ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. Cancer Medicine, 2020, 9, 8923-8930.	1.3	4

#	Article	IF	Citations
847	Future Perspectives. Hematology/Oncology Clinics of North America, 2020, 34, 1205-1214.	0.9	4
848	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1402-1405.	2.0	4
849	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. Blood Cancer Journal, 2020, 10, 39.	2.8	4
850	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	1.1	4
851	Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. British Journal of Haematology, 2021, 192, e28-e31.	1.2	4
852	MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. Clinical Biochemistry, 2021, 97, 67-73.	0.8	4
853	The Role of Autologous Stem Cell Transplantation in Amyloidosis. Oncology, 2021, 35, 471-478.	0.4	4
854	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. Blood, 2020, 136, 52-53.	0.6	4
855	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 36-37.	0.6	4
856	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 30-31.	0.6	4
857	Monoclonal Gammopathy of Undetermined Significance: Estimated Incidence and Duration Prior to Recognition.. Blood, 2007, 110, 246-246.	0.6	4
858	A Novel Prognostic Staging System for Light Chain Amyloidosis (AL) Incorporating Markers of Plasma Cell Burden and Organ Involvement.. Blood, 2009, 114, 2797-2797.	0.6	4
859	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. Blood, 2010, 116, 370-370.	0.6	4
860	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. Blood, 2011, 118, 3963-3963.	0.6	4
861	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	0.6	4
862	Unraveling Early Mortality In Patients with AL Amyloidosis. Blood, 2010, 116, 4990-4990.	0.6	4
863	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. Blood, 2021, 138, 2720-2720.	0.6	4
864	Residual serum monoclonal protein predicts progressionâ€free survival in patients with previously untreated multiple myeloma. Cancer, 2010, 116, 640-646.	2.0	3

#	Article	IF	Citations
865	A Reappraisal of Immunoglobulin Variable Gene Primers and Its Impact on Assessing Clonal Relationships Between PB B Cells and BM Plasma Cells in AL Amyloidosis. Journal of Clinical Immunology, 2011, 31, 1029-1037.	2.0	3
866	Clinical Reasoning: A 40-year-old man with CIDP-like illness resistant to treatment. Neurology, 2013, 81, e65-70.	1.5	3
867	S0120 G.E.M.S.: genomics encounters MGUS and SMM. Blood, 2014, 123, 4-5.	0.6	3
868	Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 165-166.	1.4	3
869	POEMS Syndrome and Castlemanâ€™s Disease. , 2017, , 41-69.		3
870	Serum free light chain measurements to reduce 24â€h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. American Journal of Hematology, 2018, 93, 1207-1210.	2.0	3
871	P336A descriptive analysis of patients with wild-type ATTR cardiomyopathy from the transthyretin amyloidosis outcomes survey. European Heart Journal, 2019, 40, .	1.0	3
872	Colon perforation in multiple myeloma patients â€“ A complication of highâ€dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	1.3	3
873	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	2.8	3
874	Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome. British Journal of Haematology, 2020, 190, 79-83.	1.2	3
875	AL patients donâ€™t dare go without dara. Blood, 2020, 135, 1509-1510.	0.6	3
876	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	1.1	3
877	Clinical activity of systemic VSV-IFNÎ²-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.. Journal of Clinical Oncology, 2021, 39, 2500-2500.	0.8	3
878	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplantation and Cellular Therapy, 2021, 27, 589.e1-589.e6.	0.6	3
879	POEMS Syndrome (Osteosclerotic Myeloma). , 2005, , 2453-2469.		3
880	Monoclonal gammopathies. , 2013, , 975-986.		3
881	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	0.6	3
882	Performance of Free Light Chain Assays in Clinical Practice.. Blood, 2004, 104, 757-757.	0.6	3

#	Article	IF	Citations
883	Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 2868-2868.	0.6	3
884	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 3981-3981.	0.6	3
885	Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) â€“ a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood, 2011, 118, 504-504.	0.6	3
886	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. Blood, 2013, 122, 2136-2136.	0.6	3
887	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. Blood, 2013, 122, 3119-3119.	0.6	3
888	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. Blood, 2015, 126, 3177-3177.	0.6	3
889	Thrombotic Microangiopathy in Multiple Myeloma. Blood, 2015, 126, 5317-5317.	0.6	3
890	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.	0.6	3
891	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	3.3	3
892	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer Journal, 2022, 12, 59.	2.8	3
893	Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. Blood Advances, 2022, 6, 5429-5435.	2.5	3
894	Free light-chains and renal disorders: when small is worse â€“ Authors' reply. Lancet, The, 2010, 376, 1221-1222.	6.3	2
895	Imaging Evidence for Renomegaly in Patients with POEMS Syndrome. Academic Radiology, 2011, 18, 1241-1244.	1.3	2
896	Skull base plasmacytoma: A unique case of POEMS syndrome with a plasmacytoma causing craniocervical instability. Journal of Clinical Neuroscience, 2018, 47, 254-257.	0.8	2
897	Predictors of short-term survival in WaldenstrÃ¶m Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	0.6	2
898	Outcomes of multiple myeloma patients with <scp>del 17p</scp> undergoing autologous stem cell transplantation. American Journal of Hematology, 2021, 96, E35-E38.	2.0	2
899	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leukemia and Lymphoma, 2021, 62, 316-322.	0.6	2
900	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. Leukemia Research Reports, 2021, 15, 100242.	0.2	2

#	Article	IF	Citations
901	Reply to: Comments on: Chemotherapyâ€based approach is the preferred treatment for sporadic lateâ€onset nemaline myopathy with a monoclonal protein. International Journal of Cancer, 2021, 149, 743-744.	2.3	2
902	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia and Lymphoma, 2021, 62, 3011-3018.	0.6	2
903	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2019, 134, 72-72.	0.6	2
904	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. Blood, 2019, 134, 1846-1846.	0.6	2
905	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. Blood, 2019, 134, 4386-4386.	0.6	2
906	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. Blood, 2019, 134, 1905-1905.	0.6	2
907	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. Blood, 2020, 136, 48-49.	0.6	2
908	Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.. Blood, 2004, 104, 892-892.	0.6	2
909	The Role of Stem Cell Mobilization Regimen on Lymphocyte Collection Yield and Survival after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.. Blood, 2005, 106, 1174-1174.	0.6	2
910	Lenalidomide Has Activity in a Phase II Trial in Patients with Primary Systemic Amyloidosis.. Blood, 2005, 106, 252-252.	0.6	2
911	Prevalence of Light-Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS) among Olmsted County, Minnesota Residents Aged 50 Years or Greater.. Blood, 2006, 108, 5060-5060.	0.6	2
912	Tumor Associated Macrophages (TAM) in Skeletal Plasmacytomas of Patients with Multiple Myeloma.. Blood, 2007, 110, 114-114.	0.6	2
913	Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering Multiple Myeloma.. Blood, 2007, 110, 1487-1487.	0.6	2
914	Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score. Blood, 2010, 116, 1892-1892.	0.6	2
915	Non-Clonal Serum Immunoglobulin Free Light Chains (FLC) as Markers of Overall Survival. Blood, 2010, 116, 3893-3893.	0.6	2
916	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. Blood, 2011, 118, 2942-2942.	0.6	2
917	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. Blood, 2012, 120, 1858-1858.	0.6	2
918	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. Blood, 2013, 122, 3117-3117.	0.6	2

#	Article	IF	Citations
919	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	0.6	2
920	Association of translocation t(11;14) with survival in patients with light chain (AL) amyloidosis. Journal of Clinical Oncology, 2008, 26, 8549-8549.	0.8	2
921	Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide Predict Survival in Patients with Primary Systemic Amyloidosis Undergoing Peripheral Blood Stem Cell Transplant. , 2004, , 85-87.		2
922	6q Deletion in Waldenstroı̂m Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival.. Blood, 2005, 106, 986-986.	0.6	2
923	In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders.. Blood, 2005, 106, 2567-2567.	0.6	2
924	The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM).. Blood, 2005, 106, 1545-1545.	0.6	2
925	Extent of Hematologic Response Is Important in Determining Outcome in Transplanted Patients with Primary Amyloidosis AL. Importance of Achieving CR.. Blood, 2006, 108, 611-611.	0.6	2
926	Idiopathic Bence Jones Proteinuria (Smoldering Monoclonal Light-Chain Proteinuria): Clinical Course and Prognosis. Blood, 2012, 120, 1861-1861.	0.6	2
927	Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.	0.6	2
928	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160.	0.6	2
929	Financial Toxicity and Associated Patient-Reported Quality of Life in Plasma Cell Disorders. Blood, 2021, 138, 4012-4012.	0.6	2
930	Financial Toxicity and Impact on Health-Related Quality of Life in Patients with Plasma Cell Disorders. Blood, 2020, 136, 20-21.	0.6	2
931	Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database. Blood, 2020, 136, 4-5.	0.6	2
932	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	2.0	2
933	Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method. Blood Advances, 2022, 6, 3746-3750.	2.5	2
934	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2022, 63, 2422-2427.	0.6	2
935	Current status of stem cell transplantation for multiple myeloma. Current Treatment Options in Oncology, 2005, 6, 229-240.	1.3	1
936	DIAGNOSIS AND TREATMENT OF POEMS SYNDROME. , 0, , 182-194.		1

#	Article	IF	Citations
937	Monoclonal gammopathies. , 2008, , 1167-1180.		1
938	Clinical Outcomes With and Without Sargramostim (GM-CSF) Post Autologous Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 43.	2.0	1
939	Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma. Clinical Lymphoma and Myeloma, 2009, 9, S46-S47.	1.4	1
940	The definition of IgM multiple myeloma. American Journal of Hematology, 2011, 86, 718-719.	2.0	1
941	A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. Leukemia and Lymphoma, 2013, 54, 1713-1718.	0.6	1
942	Immunoglobulins and Laboratory Recognition of Monoclonal Proteins. , 2013, , 565-588.		1
943	Reply to S. Girnius et al. Journal of Clinical Oncology, 2013, 31, 2750-2751.	0.8	1
944	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 44-45.	1.4	1
945	Opening a can of worms in AL progression. Blood, 2018, 131, 475-476.	0.6	1
946	POEMS Syndrome. Hematologic Malignancies, 2018, , 177-189.	0.2	1
947	Immunoglobulin Light Chain Amyloidosis (AL). , 2018, , 651-672.		1
948	Transthyretin amyloidosis in patients with undifferentiated heart failure. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 33-34.	1.4	1
949	Reply. Journal of the American College of Cardiology, 2019, 73, 2911-2913.	1.2	1
950	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a â€˜graft versus hostâ€™-like syndrome and poor outcomes. Bone Marrow Transplantation, 2020, 55, 1879-1881.	1.3	1
951	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 274-277.	1.3	1
952	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 309.e1-309.e5.	0.6	1
953	Chemotherapy-based stem cell mobilization in multiple myeloma patients treated with novel agents: The Mayo Clinic experience.. Journal of Clinical Oncology, 2021, 39, e20000-e20000.	0.8	1
954	Belantamab mafodotin detection by MASS-FIX and immunofixation. Clinical Chemistry and Laboratory Medicine, 2021, 59, e430-e433.	1.4	1

#	Article	IF	Citations
955	Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies. Blood, 2018, 132, 1879-1879.	0.6	1
956	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	0.6	1
957	Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. Blood, 2019, 134, 3510-3510.	0.6	1
958	A Proteomic Atlas of Cardiac Amyloidosis. Blood, 2019, 134, 1790-1790.	0.6	1
959	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. Blood, 2019, 134, 4334-4334.	0.6	1
960	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	0.6	1
961	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. Blood, 2020, 136, 22-23.	0.6	1
962	Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkinâ€™s Lymphoma.. Blood, 2004, 104, 2927-2927.	0.6	1
963	Excessive Weight Gain during Mobilization Increases First Year Mortality Following High Dose Therapy and Stem Cell Transplantation in Patients with Primary Amyloidosis.. Blood, 2004, 104, 937-937.	0.6	1
964	Immunoglobulin Free Light Chains at Diagnosis: Predictors of Progression and Survival in Solitary Plasmacytoma of Bone.. Blood, 2005, 106, 5080-5080.	0.6	1
965	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (clg-FISH).. Blood, 2007, 110, 2477-2477.	0.6	1
966	Depth of Response with Stem Cell Transplantation and Outcome for Multiple Myeloma in the Era of Novel Agents.. Blood, 2009, 114, 1228-1228.	0.6	1
967	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. Blood, 2009, 114, 956-956.	0.6	1
968	Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis. Blood, 2010, 116, 1893-1893.	0.6	1
969	A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289). Blood, 2010, 116, 3053-3053.	0.6	1
970	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicitng Outcome In Over 400 Patients. Blood, 2010, 116, 3557-3557.	0.6	1
971	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. Blood, 2010, 116, 863-863.	0.6	1
972	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. Blood, 2011, 118, 2887-2887.	0.6	1

#	Article	IF	Citations
973	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). Blood, 2011, 118, 3095-3095.	0.6	1
974	Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?. Blood, 2011, 118, 806-806.	0.6	1
975	Renal Heavy Chain and Heavy+Light Chain Amyloidosis: A Report of 17 Cases and Comparison with Renal Light Chain Amyloidosis. Blood, 2012, 120, 3992-3992.	0.6	1
976	Second Malignancies After Autologous Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2012, 120, 591-591.	0.6	1
977	Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). Blood, 2012, 120, 602-602.	0.6	1
978	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. Blood, 2012, 120, 946-946.	0.6	1
979	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2013, 122, 3095-3095.	0.6	1
980	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. Blood, 2015, 126, 1830-1830.	0.6	1
981	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.	0.6	1
982	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.	0.6	1
983	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. Blood, 2016, 128, 3444-3444.	0.6	1
984	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. Blood, 2016, 128, 4627-4627.	0.6	1
985	Neurologic aspects of monoclonal gammopathy of undetermined significance, multiple myeloma and related disorders. , 2004, , 350-365.		1
986	Immunoglobulin Light Chain Amyloidosis (Primary Amyloidosis, AL). , 2004, , 157-195.		1
987	Neuropathy Associated With Plasma Cell Proliferative Disorders. , 2004, , 35-51.		1
988	Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma.. Blood, 2004, 104, 2412-2412.	0.6	1
989	Autologous Stem Cell Transplantation for Multiple Myeloma in Patients over 70 Years: A Matched Comparison with Patients under 65 Years.. Blood, 2005, 106, 1173-1173.	0.6	1
990	Idiopathic Bence Jones Proteinuria: Clinical Course and Prognosis.. Blood, 2006, 108, 3493-3493.	0.6	1

#	Article	IF	Citations
991	Multiple Myeloma and Related Disorders. , 2008, , 2323-2351.		1
992	POEMS Syndrome and Other Atypical Plasma Cell Disorders. , 2008, , 571-623.		1
993	Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function. Blood, 2010, 116, 2970-2970.	0.6	1
994	A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis. Blood, 2010, 116, 987-987.	0.6	1
995	Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component. Blood, 2011, 118, 2945-2945.	0.6	1
996	Multiple Myeloma and Related Disorders. , 2014, , 1991-2017.e7.		1
997	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	0.6	1
998	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	0.6	1
999	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	0.6	1
1000	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	0.6	1
1001	Prognosis of Patients with WaldenstrÃ¶m Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	0.6	1
1002	Patient-Reported Outcome Driven Case Management System for Hematology â€" a Prospective Study. Blood, 2018, 132, 719-719.	0.6	1
1003	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. Blood, 2019, 134, 3171-3171.	0.6	1
1004	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	0.6	1
1005	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. Blood, 2019, 134, 5490-5490.	0.6	1
1006	Prevalence and significance of clonal hematopoiesis of indeterminate prognosis (CHIP) in multiple myeloma.. Journal of Clinical Oncology, 2020, 38, 8542-8542.	0.8	1
1007	Sporadic late-onset nemaline myopathy with monoclonal paraprotein as a malignancy rather than disimmunity and treatment with chemotherapy-based approach.. Journal of Clinical Oncology, 2020, 38, 8545-8545.	0.8	1
1008	Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy.. Journal of Clinical Oncology, 2020, 38, e20510-e20510.	0.8	1

#	Article	IF	Citations
1009	Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).. Journal of Clinical Oncology, 2020, 38, e19112-e19112.	0.8	1
1010	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. Blood, 2021, 138, 819-819.	0.6	1
1011	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	0.6	1
1012	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Blood, 2021, 138, 3774-3774.	0.6	1
1013	Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX). Blood, 2020, 136, 40-41.	0.6	1
1014	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. Blood, 2020, 136, 31-32.	0.6	1
1015	Sarcopenia identified by computed tomography (CT) imaging using a machine learningâ€“based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2022, 40, 110-110.	0.8	1
1016	Palmoplantar Keratoderma VÃ¶rner-Unna-Thost. , 2009, , 1560-1561.		0
1017	Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma. Leukemia and Lymphoma, 2009, 50, 1033-1035.	0.6	0
1018	Treatment of End Stage Heart Failure Related to Cardiac Amyloidosis. , 2013, , .		0
1019	POEMS syndrome and paraproteinemic syndromes: management and follow-up. , 0, , 225-244.		0
1020	Cardiac Amyloidosis: Typing, Diagnosis, Prognosis and Management. , 2013, , .		0
1021	POEMS Syndrome. , 2018, , 609-616.		0
1022	Cardiac amyloidosis in aortic stenosisâ€”icebergs and Archimedes' principle. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 966-967.	0.4	0
1023	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2021, 39, e20016-e20016.	0.8	0
1024	RV free wall longitudinal strain as an independent predictor of survival in wtATTR-CA patients. European Heart Journal, 2021, 42, .	1.0	0
1025	Superior Survival in Primary Systemic Amyloidosis Patients Undergoing Peripheral Blood Stem Cell Transplant. , 2004, , 121-123.		0
1026	PS-341 Induces Selective Radiosensitization of Multiple Myeloma Cells.. Blood, 2004, 104, 2478-2478.	0.6	0

#	Article	IF	Citations
1027	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. Blood, 2004, 104, 928-928.	0.6	0
1028	The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia.. Blood, 2004, 104, 1493-1493.	0.6	0
1029	Oncolytic Measles Virus Selectively Targets CD46 Overexpression on Myeloma Cells.. Blood, 2004, 104, 2392-2392.	0.6	0
1030	Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide Predict Survival in Patients with Primary Systemic Amyloidosis Undergoing Peripheral Blood Stem Cell Transplant. , 2004, , 85-87.		0
1031	Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation.. Blood, 2004, 104, 4852-4852.	0.6	0
1032	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide. , 2004, , 67-69.		0
1033	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 5420-5420.	0.6	0
1034	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. Blood, 2005, 106, 3381-3381.	0.6	0
1035	Response to Rituximab in Type II Cryoglobulinemia.. Blood, 2005, 106, 3499-3499.	0.6	0
1036	Role of Second Stem Cell Transplant in Patients with Amyloidosis Who Are Refractory or Relapsing.. Blood, 2005, 106, 5469-5469.	0.6	0
1037	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Transplanted for Multiple Myeloma.. Blood, 2005, 106, 1165-1165.	0.6	0
1038	Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).. Blood, 2005, 106, 5422-5422.	0.6	0
1039	Clinical Outcome of IgM Amyloidosis (AL) Following Stem Cell Transplantation.. Blood, 2005, 106, 5470-5470.	0.6	0
1040	One Half of Patients with Waldenstroì‘m Macroglobulinemia Have Large Deletions of Chromosome 6q.. Blood, 2005, 106, 1546-1546.	0.6	0
1041	High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.. Blood, 2006, 108, 3407-3407.	0.6	0
1042	Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.. Blood, 2006, 108, 3500-3500.	0.6	0
1043	The Serum M-Spike and Transplant Outcome in Patients with Multiple Myeloma.. Blood, 2006, 108, 5441-5441.	0.6	0
1044	Elimination of the Need for Urine Studies during Diagnostic Studies of Monoclonal Gammopathies by the Combined Use of Serum Immunofixation and Serum Free Light Chain Assays.. Blood, 2006, 108, 5011-5011.	0.6	0

#	Article	IF	Citations
1045	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. Blood, 2006, 108, 3587-3587.	0.6	0
1046	Sequential Heart and Autologous Stem Cell Transplantation for AL Amyloidosis.. Blood, 2006, 108, 3092-3092.	0.6	0
1047	Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma.. Blood, 2007, 110, 1181-1181.	0.6	0
1048	Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.. Blood, 2007, 110, 3608-3608.	0.6	0
1049	Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System.. Blood, 2007, 110, 659-659.	0.6	0
1050	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. Blood, 2007, 110, 1492-1492.	0.6	0
1051	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. Blood, 2007, 110, 2995-2995.	0.6	0
1052	Polyclonal Hypergammaglobulinemia in a Randomized Sample of Ghanaian Adult Males.. Blood, 2007, 110, 960-960.	0.6	0
1053	High Bone Turnover and Increased Angiogenesis Cytokines in Patients with POEMS Syndrome.. Blood, 2007, 110, 3525-3525.	0.6	0
1054	Comparison of High-Dose Cyclophosphamide and Growth Factor with Growth Factor Alone for Mobilization of Stem Cells for Transplantation in Patients with Multiple Myeloma.. Blood, 2008, 112, 2301-2301.	0.6	0
1055	The Prevalence of Abnormal Coagulation Parameters in Patients with Newly Diagnosed Primary Systemic Amyloidosis and Its Impact on Outcome. Blood, 2008, 112, 5114-5114.	0.6	0
1056	Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization. Journal of Clinical Oncology, 2009, 27, 7039-7039.	0.8	0
1057	Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.. Blood, 2009, 114, 2877-2877.	0.6	0
1058	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 3884-3884.	0.6	0
1059	Assessing Response and Prognosis in AL Amyloidosis. , 2010, , 77-93.		0
1060	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. Blood, 2010, 116, 1965-1965.	0.6	0
1061	Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary Disease. Blood, 2010, 116, 3047-3047.	0.6	0
1062	Role of Hepcidin In Anemia of Waldenstroì^m Macroglobulinemia. Blood, 2010, 116, 4984-4984.	0.6	0

#	Article	IF	Citations
1063	Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. Blood, 2010, 116, 4518-4518.	0.6	0
1064	Proteomic Analysis of Immunoglobulin Light Chains (LC) In AL Amyloidosis Shows That the Sequence of Clonal LC Secreted by the Neoplastic Plasma Cells Is Identical to the LC Deposited In the Amyloid Plaques. Blood, 2010, 116, 1909-1909.	0.6	0
1065	Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation.. Blood, 2010, 116, 3468-3468.	0.6	0
1066	Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma. Blood, 2010, 116, 1958-1958.	0.6	0
1067	Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. Blood, 2010, 116, 3469-3469.	0.6	0
1068	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. Blood, 2011, 118, 3101-3101.	0.6	0
1069	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. Blood, 2011, 118, 2992-2992.	0.6	0
1070	Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine. Blood, 2011, 118, 636-636.	0.6	0
1071	CD147 Is a Novel Regulator of Progression and Proliferation of Multiple Myeloma Plasma Cells. Blood, 2011, 118, 470-470.	0.6	0
1072	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. Blood, 2011, 118, 2682-2682.	0.6	0
1073	Treatment Patterns and Outcomes in Elderly Patients with Multiple Myeloma,. Blood, 2011, 118, 3980-3980.	0.6	0
1074	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. Blood, 2012, 120, 448-448.	0.6	0
1075	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). Blood, 2012, 120, 600-600.	0.6	0
1076	Molecular Interrogation of Biclonal Multiple Myeloma for Clonal Relatedness.. Blood, 2012, 120, 2928-2928.	0.6	0
1077	Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients. Blood, 2012, 120, 934-934.	0.6	0
1078	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. Blood, 2012, 120, 599-599.	0.6	0
1079	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2012, 120, 1988-1988.	0.6	0
1080	Hematopoietic Cell Transplant Co-Morbidity Index (HCTCI) and Multiple Myeloma (MM) Survival After Autologous Hematopoietic Cell Transplantation (AHCT). Blood, 2012, 120, 4217-4217.	0.6	0

#	Article	IF	Citations
1081	Treatment Trade-Offs in Myeloma: a Survey of Consecutive Patients. Blood, 2012, 120, 2059-2059.	0.6	0
1082	POEMS Syndrome (Takatsuki Syndrome). , 2014, , 179-193.		0
1083	Development Of Solid Malignancies In Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS): A Population-Based Study Of 17,315 Patients. Blood, 2013, 122, 3134-3134.	0.6	0
1084	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. Blood, 2013, 122, 1979-1979.	0.6	0
1085	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.	0.6	0
1086	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. Blood, 2013, 122, 754-754.	0.6	0
1087	Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs. Blood, 2013, 122, 1928-1928.	0.6	0
1088	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. Blood, 2013, 122, 1842-1842.	0.6	0
1089	Mass Spectrometry-Based Proteomics Reveals Distinct Immunoglobulin Light Chain Variable Region Usage In Systemic Versus Localized AL Amyloidosis. Blood, 2013, 122, 3142-3142.	0.6	0
1090	Abstract 18141: Is There Systolic Myocardial Mechanical Dysfunction in Patients With Different Degrees of Diastolic Dysfunction and Normal Ejection Fraction?. Circulation, 2014, 130, .	1.6	0
1091	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). Blood, 2015, 126, 3292-3292.	0.6	0
1092	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. Blood, 2015, 126, 3039-3039.	0.6	0
1093	AL Amyloidosis and Patient Reported Quality of Life. Blood, 2015, 126, 3317-3317.	0.6	0
1094	A Rapid MALDI-TOF Method for Isotyping and Quantitating M-Proteins in a Single Assay: Longitudinal Comparison to Serum Protein Electrophoresis and Hevylite for Monitoring Patients with Monoclonal Gammopathies. Blood, 2015, 126, 1780-1780.	0.6	0
1095	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. Blood, 2015, 126, 4176-4176.	0.6	0
1096	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. Blood, 2015, 126, 5303-5303.	0.6	0
1097	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Blood, 2015, 126, 3044-3044.	0.6	0
1098	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5615-5615.	0.6	0

#	Article	IF	Citations
1099	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2016, 128, 996-996.	0.6	0
1100	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.	0.6	0
1101	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	0.6	0
1102	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	0.6	0
1103	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.	0.6	0
1104	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.	0.6	0
1105	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.	0.6	0
1106	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. Blood, 2016, 128, 3255-3255.	0.6	0
1107	Outcome of Very Young (â‰¤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. Blood, 2016, 128, 5576-5576.	0.6	0
1108	Urinary Exosomes Detect Amyloidogenic Light Chain in Patients Who Have Renal Progression Despite a Hematologic Complete Response. Blood, 2016, 128, 3268-3268.	0.6	0
1109	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. Blood, 2016, 128, 2187-2187.	0.6	0
1110	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	0.6	0
1111	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	0.6	0
1112	Genomic Abnormalities Among African Individuals with Monoclonal Gammopathies Using Calculated Ancestry. Blood, 2018, 132, 4458-4458.	0.6	0
1113	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	0.6	0
1114	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	0.6	0
1115	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	0.6	0
1116	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	0.6	0

#	Article	IF	Citations
1117	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	0.6	0
1118	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.	0.6	0
1119	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	0.6	0
1120	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	0.6	0
1121	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	0.6	0
1122	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	0.6	0
1123	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	0.6	0
1124	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	0.6	0
1125	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. Blood, 2018, 132, 3436-3436.	0.6	0
1126	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2018, 132, 4615-4615.	0.6	0
1127	Abstract 17078: Myocardial Stiffness by Intrinsic Wave Propagation Method: Comparison With End-Diastolic Pressure-Volume Relationship. Circulation, 2018, 138, .	1.6	0
1128	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. Blood, 2019, 134, 4505-4505.	0.6	0
1129	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). Blood, 2019, 134, 5523-5523.	0.6	0
1130	WaldenstrÃ¶m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	0.6	0
1131	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 4396-4396.	0.6	0
1132	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. Blood, 2019, 134, 3080-3080.	0.6	0
1133	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5833-5833.	0.6	0
1134	The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias. Blood, 2019, 134, 4362-4362.	0.6	0

#	Article	IF	Citations
1135	Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis. Blood, 2019, 134, 1770-1770.	0.6	0
1136	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. Blood, 2019, 134, 5532-5532.	0.6	0
1137	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 2197-2197.	0.6	0
1138	The Transcriptome of Immunomodulator-Resistant Multiple Myeloma. Blood, 2019, 134, 1772-1772.	0.6	0
1139	Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma. Blood, 2019, 134, 3061-3061.	0.6	0
1140	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. Blood, 2019, 134, 2013-2013.	0.6	0
1141	Prognostic role of beta-2 microglobulin in patients with light chain amyloidosis treated with autologous stem cell transplantation.. Journal of Clinical Oncology, 2020, 38, e20506-e20506.	0.8	0
1142	Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. Journal of Clinical Oncology, 2020, 38, 8516-8516.	0.8	0
1143	Correlation between 24-hour proteinuria and spot urine albumin to creatinine ratio in systemic light chain amyloidosis.. Journal of Clinical Oncology, 2020, 38, 8549-8549.	0.8	0
1144	Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels.. Journal of Clinical Oncology, 2020, 38, e20515-e20515.	0.8	0
1145	Cytogenetic abnormalities in MM: Association with disease characteristics and treatment response.. Journal of Clinical Oncology, 2020, 38, e20520-e20520.	0.8	0
1146	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. Transplantation, 2021, 105, 1615-1624.	0.5	0
1147	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNÎ²-NIS). Blood, 2021, 138, 1333-1333.	0.6	0
1148	Prognostic Role of IL-6 in POEMS Syndrome. Blood, 2021, 138, 2700-2700.	0.6	0
1149	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio â‰¥100. Blood, 2021, 138, 1617-1617.	0.6	0
1150	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma-Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	0.6	0
1151	Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplant (ASCT) for Patients with POEMS Syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.6	0
1152	The Role of Non-Coding RNAs in the Pathogenesis of AL Amyloidosis. Blood, 2021, 138, 2659-2659.	0.6	0

#	Article	IF	Citations
1153	Relationship and Susceptibility to Serious Infections Among Monoclonal B-Cell Lymphocytosis (MBL), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Clonal Hematopoiesis (CH) Premalignant Conditions. Blood, 2021, 138, 3739-3739.	0.6	0
1154	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	0.6	0
1155	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood, 2021, 138, 1630-1630.	0.6	0
1156	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2021, 138, 119-119.	0.6	0
1157	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	0.6	0
1158	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	0.6	0
1159	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10.	0.6	0
1160	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	0.6	0
1161	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	0.6	0
1162	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	0.6	0
1163	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	0.6	0
1164	Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota. Blood, 2020, 136, 15-16.	0.6	0
1165	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-22.	0.6	0
1166	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	0.6	0
1167	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged â‰¥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	0.6	0
1168	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	0.6	0
1169	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. Blood, 2020, 136, 1-2.	0.6	0
1170	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42.	0.6	0

#	Article	IF	Citations
1171	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	1.3	0
1172	Amyloidosis and other rare plasma cell dyscrasias. , 0, , 184-206.		0
1173	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO Oncology Practice, 2022, , OP2100789.	1.4	0
1174	Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome. Frontiers in Endocrinology, 0, 13, .	1.5	0
1175	Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2022, 40, e20001-e20001.	0.8	0